WO1994007867A1 - Substituted pyrimidines for control of diabetic complications - Google Patents

Substituted pyrimidines for control of diabetic complications Download PDF

Info

Publication number
WO1994007867A1
WO1994007867A1 PCT/US1993/006446 US9306446W WO9407867A1 WO 1994007867 A1 WO1994007867 A1 WO 1994007867A1 US 9306446 W US9306446 W US 9306446W WO 9407867 A1 WO9407867 A1 WO 9407867A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
heteroaryl
phenyl
independently selected
Prior art date
Application number
PCT/US1993/006446
Other languages
French (fr)
Inventor
Banavara L. Mylari
Peter J. Oates
Todd W. Siegel
William J. Zembrowski
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to AU46697/93A priority Critical patent/AU683620B2/en
Priority to US08/406,947 priority patent/US5728704A/en
Priority to CA002145640A priority patent/CA2145640C/en
Priority to EP93917043A priority patent/EP0662962A1/en
Priority to KR1019950701168A priority patent/KR950703539A/en
Publication of WO1994007867A1 publication Critical patent/WO1994007867A1/en
Priority to NO951155A priority patent/NO306598B1/en
Priority to US08/980,559 priority patent/US5866578A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to novel pyrimidine derivatives and to the use of such derivatives and related compounds to inhibit sorbitol dehydrogenase, lower fructose levels, or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic microangiopathy and diabetic macroangiopathy in mammals.
  • This invention also relates to pharmaceutical compositions containing such pyrimidine derivatives and related compounds.
  • pyrimidine derivatives of the formula I, as defined below, and their pharmaceutically acceptable salts lower fructose levels in the tissues of mammals affected by diabetes (e.g., nerve, kidney and retina tissue) and are useful in the treatment and prevention of the diabetic complications referred to above.
  • These compounds, or their metabolites in vivo are inhibitors of the enzyme sorbitol dehydrogenase, which catalyzes the oxidation of sorbitol to fructose.
  • the present invention also relates to the use of substituted pyrimidines of the formula I, as defined below, to treat or prevent diabetic complications in mammals, and to pharmaceutical compositions containing such pyrimidines.
  • R 1 is hydrogen, CF 3 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl-S-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl-SO-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl-SO 2 -(C 1 -C 6 )alkyl, hydroxy-(C 1 -C 6 )alkyl, dihydroxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxycarbonyl-(C 1 -C 6 )alkyl, aryl selected from phenyl and naphthyl, aryl-(C 1 -C 6 )alkyl wherein the aryl moiety is selected from phenyl and naphthyl, (C 1 -C 6 )alkoxycarbonylaryl
  • R 1 is a group of the formula
  • W, Q and Z are independently selected from hydrogen, (C 1 -C 6 )alkyl and trifluoromethyl, phenyl, furyl, triazolyl, thiazolyl and thienyl, wherein said phenyl, furyl, triazotyl, thiazolyl and thienyl may optionally be substituted with one or more substituents independently selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, trifluoromethyl and hydroxy; or R 1 is a group of the formula , wherein R 6 is hydrogen, (C 1 -C 6 )alkyl, aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzo
  • R 2 and R 3 are independently selected from hydrogen, (C 1 -C 6 )alkyl, phenyl and phenyl-(C 1 -C 4 )alkyl, wherein said phenyl and the phenyl moiety of said phenyl -(C 1 -C 4 )alkyl may optionally be substituted with one or more substituents independently selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, chloro, bromo and trifluoromethyl;
  • R 2 and R 3 form, together with the nitrogen to which they are attached, a cyclic group selected from azetidino, pyrrolidino, piperidino, piperazino and morpholino, wherein said cyclic group may optionally be substituted with from zero to two substituents, independently selected from (C 1 -C 6 )alkyl, -CONH 2 , -SO 2 NH 2 , N-(C 1 -C 4 )alkylsulfamoyl, N,N-di-(C 1 -C 4 )alkylsulfamoyl, (C 1 -C 6 )alkoxycarbonyl, N,N-di-(C 1 -C 4 )alkylcarbamoyl, N-(C 1 -C 4 )alkylcarbamoyl, N-phenylcarbamoyl, (C 1 -C 6 )alkylcarbonyl, phenylcarbon
  • R 4 is hydrogen, chloro, bromo, cyano, nitro, trifluoromethyl, amino, (C 1 -C 6 )alkyl, (C 1 -C 6 )hydroxyalkyl, (C 1 -C 6 )alkoxy, phenyl, naphthyl or furyl, wherein said phenyl, naphthyl and furyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, trifluoromethyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, - S- (C 1 -C 6 )alkyl, -SO-(C 1 -C 6 )alkyl, -SO 2 -(C 1 -C 6 )alkyl and hydroxy; and
  • R 5 is hydrogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, trifluoromethyl, (C 1 -C 6 )hydroxyalkyl,
  • this invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a sorbitol dehydrogenase inhibiting effective amount of a compound of the formula I , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • This invention also relates to a method of inhibiting the enzyme sorbitol dehydrogenase in a mammal, including a human, comprising administering to said mammal a sorbitol dehydrogenase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, and a pharmaceutically acceptable carrier.
  • This invention also relates to a method of lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, and a pharmaceutically acceptable carrier.
  • This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
  • a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy
  • This invention also relates to those compounds of the formula I wherein R 1 is
  • R 1 is a group of the formula wherein the dotted line represents an optional double bond, W, Q and Z are independently selected from hydrogen, (C 1 -C 6 )alkyl and trifluoromethyl, phenyl, furyl, triazolyl, thiazolyl and thienyl, wherein said phenyl, furyl, triazolyl, thiazolyl and thienyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, trifluoromethyl and hydroxy; or R 1 is a group of the formula , wherein R 6 is hydrogen, (C 1 -C 6 )alkyl, aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl,
  • R 1 is a group of the formula , wherein R 7 is aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, benzothienyl and quinolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -S-(C 1 -C 6 )alkyl, -SO-(C 1 -C 6 )alkyl, -SO 2 - (C 1 -C 6 )alkyl and trifluoromethyl, and Y is hydrogen, benzyl, acet
  • This invention also relates to mutual prodrugs of a compound of the formula I and an aldose reductase inhibiting compound.
  • This invention also relates to compounds of the formula
  • R 25 is or O 2 NH 2 CO 2 S-R 26
  • R 26 is aryl selected from phenyl and naphthyl, wherein said aryl may optionally be substituted with one or more substituents, preferably with one or two substituents, independently selected from chloro, bromo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -S-(C 1 -C 6 )alkyl, -SO-(C 1 -C 6 )alkyl, -SO 2 -(C 1 - C 6 )alkyl, hydroxy-(C 1 -C 6 )alkyl and trifluoromethyl;
  • R 2 and R 3 are independently selected from hydrogen, (C 1 -C 6 )alkyl, phenyl and phenyl-(C 1 -C 4 )alkyl, wherein said phenyl and the phenyl moiety of said phenyl -(C 1 -C 4 )alkyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, chloro, bromo and trifluoromethyl;
  • R 2 and R 3 form, together with the nitrogen to which they are attached, a cyclic group selected from azetidino, pyrrolidino, piperidino, piperazino and morpholino, wherein said cyclic group may optionally be substituted with from zero to two substituents independently selected from (C 1 -C 6 )alkyl, -CONH 2 , -SO 2 NH 2 , N-(C 1 - C 4 )alkylsulfamoyl, N,N-di-(C 1 -C 4 )alkylsulfamoyl, (C 1 -C 6 )alkoxycarbonyl, N,N-di-(C 1 - C 4 )alkylcarbamoyl, N-(C 1 -C 4 )-alkylcarbamoyl, N-phenylcarbamoyl, (C 1 - C 6 )alkylcarbonyl, phenylcar
  • R 4 is hydrogen, chloro, bromo, cyano, nitro, trifluoromethyl, amino, (C 1 -C 6 )alkyl, (C 1 -C 6 )hydroxyalkyl, (C 1 -C 6 )alkoxy, phenyl, naphthyl or furyl, wherein said phenyl, naphthyl and furyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, trifluoromethyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -S-(C 1 -C 6 )alkyl, -SO-(C 1 -C 6 )alkyl, -SO 2 -(C 1 -C 6 )alkyl and hydroxy;
  • R 5 is hydrogen, (C 1 -C 6 )alkyI, (C 1 -C 6 )alkoxy, trifluoromethyl, (C 1 -C 6 )hydroxyalkyl, -S-(C 1 -C 6 )alkyl, -SO-(C 1 -C 6 )alkyl, -SO 2 -(C 1 -C 6 )alkyl, phenyl or furyl, wherein said phenyl and furyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, trifluoromethyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -S-(C 1 -C 6 )alkyl, -SO-(C 1 -C 6 )alkyl, -SO 2 -(C 1 -C 6 )alkyl and hydroxy;
  • R 8 is hydrogen or R 7 ;
  • R 7 is aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, benzothienyl and quinolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -S-(C 1 -C 6 )alkyl, -SO-(C 1 -C 6 )alkyl, -SO 2 -(C 1 -C 6 )alkyl and trifluoromethyl, and Y is hydrogen, benzyl, acetyl, benzoyl, aryl selected from
  • Y 4 is hydrogen or(C 1 -C 5 )alkyl
  • Y 3 is selected from the following groups:
  • A is CH 2 , CH 2 CH 2 , CH(CH 3 ) or ;
  • B is oxygen or sulfur
  • R 9 is selected from phenyl, benzothiazol-2-yl, benzoxazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl, thiazolopyridin-2-yl, oxazolopyridin-2-yl, 3-phenyl-1 ,2,4-oxadiazol-5-yl, and 5-phenyl-1 ,2,4-oxadiazol-3-yl, and R 9 may optionally be substituted with from one to three substituents independently selected from fluorine, chlorine, bromine, methyl, methylthio, methoxy, hydroxy and trifluoromethyl;
  • R 10 and R 11 are independently selected from hydrogen, fluorine, chlorine, bromine, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkoxy and trifluoromethyl;
  • D and E are independently selected from -CH 2 -, oxygen and sulfur, except that D and E cannot both be oxygen and cannot both be sulfur;
  • R 12 and R 13 are independently selected from hydrogen, fluorine, chlorine, bromine, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkoxy and trifluoromethyl; and
  • F and G are independently selected from -CH- and nitrogen;
  • R 12 and R 13 are independently selected from hydrogen, fluorine, chlorine, bromine, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkoxy and trifluoromethyl;
  • K is oxygen, sulfur, SO or SO 2 ;
  • R 14 is hydrogen, fluoro, chloro, bromo, methyl, nitro, cyano, methanesulfonyl or benzoyl;
  • R 15 is hydrogen, fluoro, chloro, bromo, carboxy, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or benzyloxy;
  • R 16 is hydrogen, fluoro, chloro, bromo or (C 1 -C 3 )alkyl
  • R 17 is (C 1 -C 4 )alkyl, trifluoromethyl or (CH 2 ) n Ar, wherein n is 0, 1 or 2 and Ar is phenyl optionally substituted with one or two substituents independently selected from methoxy, fluoro, chloro and bromo;
  • R 18 is hydrogen, methyl or ethyl
  • R 19 is hydrogen or methyl
  • R 25 is are conjugates and mutual prodrugs of such aldose reductase inhibitors and the pharmaceutically active compounds of the formula I wherein R 1 is - CH 2 OH, -CHR 7 OH or hydroxy-(C 1 -C 6 )alkyl.
  • mutual prodrugs they are expected to release in vivo both pharmaceutically active agents - a compound of the formula I wherein R 1 is -CH 2 OH, -CHR 7 OH or hydroxy-(C 1 -C 6 )alkyl and an aldose reductase inhibitor of the formula .
  • R 1 is -CH 2 OH, -CHR 7 OH or hydroxy-(C 1 -C 6 )alkyl.
  • mutual prodrugs they are expected to release in vivo both pharmaceutically active agents - a compound of the formula I wherein R 1 is -CH 2 OH, -CHR 7 OH or hydroxy-(C 1 -C 6 )alkyl and an aldose reductase inhibitor of the formula O 2 N-CH 2 -SO 2 -R 26 -NH 2 .
  • Preferred embodiments of this invention include those compounds of the formula VI, and pharmaceutically acceptable salts thereof, wherein R 25 is , Y 2 is not absent and: (a) Y 3 is a group of the formula VII, R 9 is phenyl, substituted phenyl, benzothiazol-2-yl or benzoxazol-2-yl, A is -CH 2 -, and R 10 and R 11 are either both methyl or they form, together with the carbons to which they are attached, a group of the formula
  • Y 3 is a group of the formula VIII, R 9 is phenyl, substituted phenyl, benzothiazol-2-yl or benzoxazol-2-yl, A is -CH 2 -, and R 12 and R 13 are independently selected from bromo and chloro;
  • Y 3 is a group of the formula IX and each of R 12 and R 13 is hydrogen;
  • Y 3 is a group of the formula X and R 12 and R 13 are independently selected from (C 1 -C 6 )alkoxy and trifluoromethyl;
  • Y 3 is a group of the formula XI and R 12 and R 13 are independently selected from (C 1 -C 6 )alkyl;
  • Y 3 is a group of the formula XII, R 9 is phenyl, substituted phenyl or benzothiazol-2-yl, A is -CH 2 - and R 12 and R 13 are independently selected from chloro and bromo; or
  • Preferred embodiments of this invention also include those compounds of the formula VI that are mutual prodrugs of a compound of the formula I and an aldose reductase inhibitor of the formula , wherein such aldose reductase inhibitor is selected from:
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising: (a) an amount of a mutual prodrug of a compound of the formula I and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug, effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes; and (b) a pharmaceutically acceptable carrier.
  • This invention also relates to a method of lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a mutual prodrug of a compound of the formula I and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug.
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising: (a) an amount of a mutual prodrug of a compound of the formula I and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human; and (b) a pharmaceutically acceptable carrier.
  • This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a mutual prodrug of a compound of the formula I and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug, effective in treating or preventing such complication.
  • a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human
  • This invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an amount of a compound of the formula VI , or a pharmaceutically acceptable salt thereof, effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, and a pharmaceutically acceptable carrier.
  • This invention also relates to a method of lowering thelevel of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula VI, or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an amount of a compound of the formula VI, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, and a pharmaceutically acceptable carrier.
  • This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula VI, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
  • a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy
  • L is oxygen, CH 2 sulfur or ;
  • J is hydrogen, methyl or -CNH 2 ;
  • G is CH or N
  • R 20 and R 21 are independently selected from hydrogen, fluorine, chlorine, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, -S-(C 1 -C 6 )alkyl, -SO-(C 1 -C 6 )alkyl or -SO 2 -(C 1 -C 6 )alkyl;
  • M is phenyl, naphthyl or a heteroaryl group selected from furan, morpholine, pyrrolidine, tetrahydroisoquinoline, thiophene, thiazole, oxazole, benzofuran, benzothiophene, benzothiazole, benzoxazole and indole, wherein said phenyl, naphthyl and heteroaryl groups may optionally be substituted with up to three substituents independently selected from chloro, fluoro, bromo, cyano, nitro, hydroxy, carboxy, amino (C 1 -C 6 )alkylamino, (C 1 -C 6 )dialkylamino, (C 1 -C 6 )alkanoylamino, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 3 -C 6 )alkenyloxy,
  • Y 5 is oxygen or sulfur, or Y 5 is absent (i.e., the phenyl ring is bonded to the carbon to which R 22 and R 23 are attached), and R 22 and R 23 are independently selected from hydrogen and (C 1 -C 4 )alkyl, and the phenyl moiety to which the -NHCOC(R 22 )(R 23 )- Y 5 - sidechain is attached may optionally be substituted with from one to three substituents independently selected from hydrogen, halo, trifluoromethyl, nitro, cyano, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy and (C 1 -C 4 )alkanoyl, or any adjacent pair of substituents may form, together with the carbons to which they are attached, a benzo ring which may optionally be substituted with a substituent independently selected from halo, (C 1 - C 4 )alkyl and (C 1 -C 4 )alkoxy
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising: (a) an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetics; (b) an amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes and (c) a pharmaceutically acceptable carrier.
  • This invention also relates to a method of lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, in combination with a fructose lowering effective amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising: (a) an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human; (b) an amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy or diabetic microangiopathy or macroangiopathy in a mammal, including a human; and (c) a pharmaceutically acceptable carrier.
  • This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication, in combination with an amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
  • a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising: (a) an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetics; (b) an amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes and (c) a pharmaceutically acceptable carrier.
  • This invention also relates to a method of lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, in combination with a fructose lowering effective amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising: (a) an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human; (b) an amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy or diabetic microangiopathy or macroangiopathy in a mammal, including a human; and (c) a pharmaceutically acceptable carrier.
  • a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy or diabetic microangiopathy or macroang
  • This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication, in combination with an amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
  • a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human
  • Preferred embodiments of this invention include those pharmaceutical compositions and methods set forth above, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed is a compound wherein R 1 is (C 1 -C 6 )hydroxyalkyI, (C 1 -C 6 )alkoxy, imidazolyl, furyl, pyrazolyl, tetrahydrofuryl, thienyl or triazolyl, or R 1 is Y-O-CH-R 7 wherein R 7 is benzothiazolyl, furyl, imidazolyl, pyrazolyl, thienyl, triazolyl, (C 1 -C 6 )alkyl or trifluoromethyl, and Y is hydrogen or (C 1 -C 6 )alkyl, and R 2 and R 3 form, together with the nitrogen to which they are attached, a group of the formula wherein X is carbon or -SO- and R 24 is amino, (C 1 -C 6 )alkylamino, di-
  • Particularly preferred embodiments of this invention are those pharmaceutical compositions and methods referred to above, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed is a compound wherein R 1 is (C 1 -C 6 )alkyl, (C 1 -C 6 )hydroxyalkyl, (C 1 -C 6 )alkoxy, furyl, triazolyl, or tetrahydrofuryl, or
  • R 1 is wherein R 7 is benzothiazolyl, furyl, thiazolyl, thienyl or trifluoromethyl, and Y is hydrogen or (C 1 -C 6 )alkyl, each of R 4 and R 5 is hydrogen, and R 2 and R 3 , together with the nitrogen to which they are attached, form a group of the formula wherein R 27 and R 28 are, independently, methyl or ethyl.
  • compositions and methods referred to above wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed is a compound wherein R 1 is (C 1 -C 6 )hydroxyalkyl, furyl or triazolyl, or R 1 is wherein R 7 is furyl, thienyl or trifluoromethyl and Y is hydrogen, each of R 4 and R 5 is hydrogen, and R 2 and R 3 , together with the nitrogen to which they are attached, form a group of the formula wherein R 27 and R 28 are, independently, hydrogen, methyl or ethyl.
  • Preferred embodiments of this invention also include the pharmaceutical compositions and methods set forth above, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed is selected from:
  • a sorbitol dehydrogenase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof refers to an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that exhibits sorbitol dehydrogenase inhibiting activity, or an amount of such compound or salt that yields a metabolite in vivo that exhibits sorbitol dehydrogenase inhibiting activity.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.
  • alkoxy includes O-alkyl groups wherein “alkyl” is defined as above.
  • one or more substituents includes from one to the maximum number of substituents possible based on the number of available bonding sites.
  • acids that may be used to prepare pharmaceutically acceptable acid addition salts of those compounds of formulae I and VI that are basic in nature are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate,ethanesulfonate,benzene-sulfonate,p-toluenesulfonateandpamoate [i.e., 1 ,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.
  • non-toxic acid addition salts i.e., salts containing pharmacologically acceptable anions,
  • the chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formulae I and VI that are acidic in nature are those that form non-toxic base salts with such compounds.
  • Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
  • Figure 1 illustrates the dose dependent lowering of erythrocyte fructose by 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 1 as "Compound 1”) in diabetic rats.
  • Figure 2 illustrates the dose dependent elevation of erythrocyte sorbitol by 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methyIpyrimidine (referred to in Figure 2 as "Compound 1") in diabetic rats.
  • Figure 3 illustrates the dose dependent lowering of nerve fructose by 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 3 as "Compound 1") in diabetic rats.
  • Figure 4 illustrates the dose dependent elevation of nerve sorbitol by 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 4 as "Compound 1") in diabetic rats.
  • Figure 5 illustrates the dose dependent in vitro inhibition of sorbitol dehydrogenase by sera from rats dosed with 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 5 as "Compound 1 ").
  • Figure 6 illustrates the dose dependent in vitro inhibition of sorbitol dehydrogenase by urinefrom rats dosed with 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 6 as "Compound 1 ").
  • Compounds of the formulae VII and VIII may be prepared as described in United States Patent 5,039,672, which issued to Eggler et al. on August 13, 1991.
  • Compounds of the formula XIX may be prepared as described in European Patent Applications EP 304190, EP 408713, EP 409449, EP 469887 and EP 469888, which were published, respectively, on February 22, 1989, January 23, 1991 , January 30, 1991 , February 5, 1992 and February 5, 1992, United States Patent 5,110,808, which issued to Brittain et al. on May 5, 1992, United States Patent 5,102,905, which issued to Brown et aL on
  • Y 3 is a group of the formula XII, as defined above, may be prepared as described by
  • R optionally substituted aryl , optionally substituted heteroaryl , dihydroxy-(C 1 -C 6 )alkyl , (C 1 -C 6 )alkyl-S-(C 1 -C 6 )alkyl) , aryl-(C 1 -C 6 )alkyloxy wherein the aryl moiety is optionally substituted, aryl-(C 1 -C 6 )alkyl wherein the aryl moiety is optionally substituted, or heteroaryl-(C 1 -C 6 )alkyl wherein the heteroaryl moiety is optionally substituted)
  • Oxidizing agents that may be used include chromic acid, silver oxide and activated manganese dioxide, with activated manganese dioxide being preferred. When chromic acid is used, the preferred solvent
  • the solvent is preferably a halocarbon solvent such as chloroform or methylene chloride, and the reaction temperature, which can range from about 0°C to about 100°C, is preferably between about 20°C and the reflux temperature of the solvent.
  • Compounds of the formula I A wherein R 1 is and R 6 is other than hydrogen may be prepared by first reacting the corresponding compound wherein R 1 is formyl (CHO) with an organolithium reagent of the formula R 6 Li or an appropriate Grignard reagent of the formula R 6 MgX wherein X is chloro, bromo or iodo, and then oxidizing the reaction product.
  • the initial reaction with the Grignard or organolithium reagent is generally conducted in a hydrocarbon solvent such as n-pentane, n-hexane or n-heptane, at a temperature from about -70°C to about 0°C, preferably from about -70°C to about -20°C.
  • the subsequent oxidation step may be carried out as described above for the oxidation of compounds wherein R 1 is hydroxymethyl.
  • R 1 is and R 6 is other than hydrogen.
  • an appropriate reagent of the formula Y-L, wherein Y is other than hydrogen and L is a leaving group in the presence of a strong base yields the corresponding compounds wherein R 1 is and Y is other than hydrogen.
  • bases that may be used are sodium hydride in dimethylformamide and a (C 1 -C 6 )alkyllithium in a hydrocarbon solvent (e.g. n-pentane or n-hexane).
  • Suitable leaving groups include chloro, bromo, iodo and OSO 2 -(C 1 -C 6 ) alkyl.
  • the reaction temperature can range from about -20°C to about 100°C, and is preferably from about 0°C to about 60°C.
  • Scheme 2 illustrates the preparation of compounds of the formula IA wherein R 1 is a group of the formula
  • such compounds may be prepared by reacting the corresponding compounds wherein R 1 is with a Wittig reagent of the formula ( Typically, this reaction is carried out in a nonprotic solvent such as dimethylformamide or a (C 4 -C 6 )alkylether, preferably tetrahydrofuran, at a temperature from about 0°C to about 100°C, preferably from about 25°C to about 100°C.
  • the reactants in which R 1 is may be obtained by oxidation of the corresponding compounds wherein R 1 is -CHOHW as described above for the oxidation of compounds wherein R 1 is -CHOHR 6 .
  • those compounds wherein R 1 is -CHOHW may be obtained by the procedure described above and depicted in scheme 1 for preparing the analogous compounds wherein R 1 is -CHOHR 6 or -CHOHR 7 .
  • Suitable hydrogenation catalysts include palladium, platinum, nickel, platinum oxide and rhodium.
  • the preferred catalyst for hydrogenation is platinum on carbon.
  • the reaction temperature may range from about 10°C to about 50°C, with about 25°C being preferred.
  • the hydrogenation is generally carried out at a pressure from about 1.5 to about 4 atmospheres, preferably at about
  • a compound of formula II or its acid addition salt is reacted with a compound of formula III to give a compound of formula IV.
  • the reaction is generally conducted or an alcoholic solvent such as methanol, ethanol or tert-butanol, at a temperature from about 25°C to about 100°C, preferably from about 25°C to about 50°C.
  • the reaction is generally conducted as above in the presence of an alkali metal or alkaline earth metal hydroxide (e.g., sodium, potassium, or calcium hydroxide) or an alkali metal alkoxide (e.g., sodium or potassium ethoxide or tert-butoxide) at temperatures ranging from about 10°C to about 80°C, preferably at temperatures between 30° and 60°C.
  • an alkali metal or alkaline earth metal hydroxide e.g., sodium, potassium, or calcium hydroxide
  • an alkali metal alkoxide e.g., sodium or potassium ethoxide or tert-butoxide
  • the compound of formula IV is converted into a pyrimidine derivative of the formula V by reacting it with an inorganic acid chloride, e.g., phosphorus oxychloride, thienyl chloride, phosphorus pentachloride or phosphorous trichloride.
  • an inorganic acid chloride e.g., phosphorus oxychloride, thienyl chloride, phosphorus pentachloride or phosphorous trichloride.
  • This reaction is usually conducted in an aromatic hydrocarbon solvent, e.g., benzene, toluene or xylene, at a temperature from about 30° to about 100°C.
  • the preferred temperature range is between 30° and 60°C.
  • Reaction of the compound of formula V with the appropriate compound of formula NHR 2 R 3 yields a compound of formula IA.
  • Suitable solvents for this reaction include ethereal solvents such as ethyl ether, tetrahydrofuran, or dioxane and halocarbon solvents such as methylene chloride or chloroform.
  • the reaction temperature may range from about 0°C to about 80°C.
  • the solvent is a halocarbon solvent and the temperature is between 0°C and 50°C.
  • R 1 is (C 1 -C 6 )alkoxycarbonyl-(C 1 -C 6 )alkyl
  • R 1 is hydroxy-(C 1 -C 6 )alkyl
  • suitable organic bases are (C 4 -C 10 )alkylamines and dialkylamines, pyridine, quinoline and isoquinoline.
  • this reaction is carried out in another or halocarbon solvent such as diethyl ether, tetrahydrofuran (THF), methylene chloride or chloroform, at a temperature from about 0°C to about 50°C, preferably from about 0°C to about room temperature.
  • another or halocarbon solvent such as diethyl ether, tetrahydrofuran (THF), methylene chloride or chloroform
  • R 1 is (C 1 -C 6 )alkyl-SO-(C 1 -C 6 )alkyl
  • R 1 is (C 1 -C 6 )alkyl-S-(C 1 -C 6 )alkyl
  • these oxidations may be conducted using m-chloroperbenzoic acid as the oxidizing agent in a halocarbon solvent such as methylene chloride or chloroform, at a temperature from about -10°C to about 10°C, preferably about 0°C.
  • compounds of the formula IA wherein R 1 is (C 1 -C 6 )alkyl-SO 2 -(C 1 -C 6 )alkyl may be prepared by oxidation of the corresponding compounds wherein R 1 is (C 1 -C 6 )alkyl-SO-(C 1 -C 6 )alkyl using methods known in the art. Such oxidations may be conducted, for example, in the manner specified above, but at a temperature ranging from about room temperature to about
  • This reaction is generally carried out in a halocarbon, aromatic hydrocarbon or ethereal solvent at a temperature from about 0°C to about 150°C, preferably from about 0°C and about 100°C.
  • Preferred solvents include benzene, toluene, xylene, methylene chloride, chloroform, ether, tetrahydrofuran and dioxane.
  • compounds of the formula VI wherein Y 2 is absent can be prepared by reacting a compound of the formula with a (C 4 -C 8 )alkylchloroformate in the presence of any organic base, and then adding a compound of the formula XX, as depicted and defined above, to the reaction mixture.
  • bases that may be used are (C 3 -C 6 )alkylamines and aromatic amines such as pyridine, quinoline or isoquinoline.
  • This reaction is typically conducted in a halocarbon solvent, preferably methylene chloride or chloroform, at a temperature from about -70°C to about 50°C, preferably from about -70°C to about 20°C.
  • the addition of the compound of formula XX is typically carried out at temperatures ranging from about -70°C to about 50°C, preferably from about -70°C and about 30°C.
  • This reaction is conducted in the presence of a base (e.g., a (C 3 -C 10 )alkylamine or an aromatic amine such as pyridine, quinoline or isoquinoline) at a temperature from about -70°C to about 0°C, preferably from about -30°C to about 0°C.
  • a base e.g., a (C 3 -C 10 )alkylamine or an aromatic amine such as pyridine, quinoline or isoquinoline
  • a base e.g., a (C 3 -C 10 )alkylamine or an aromatic amine such as pyridine, quinoline or isoquinoline
  • the compound of formula XXI formed in the above reaction is then reacted with a compound of the formula in the presence of a base (e.g., a (C 3 -C 10 )alkylamine or an aromatic amine such as pyridine, quinoline or isoquinoline).
  • a base e.g., a (C 3 -C 10 )alkylamine or an aromatic amine such as pyridine, quinoline or isoquinoline.
  • the reaction is generally conducted at a temperature ranging from about -20°C to about room temperature, preferably between about -10°C and about room temperature, in a halocarbon or ether solvent, preferably in methylene chloride or chloroform.
  • Compounds of the formula VI wherein R 25 is and Y 2 is - may be prepared in the following manner.
  • a compound of the formula is contacted with an Ameberlite ® IRA-904 resin containing quaternary ammonium groups in the hydroxide form to yield a salt of the formula (hereinafter referred to as a salt of the formula XXII).
  • the compound of formula is dissolved in a lower alcohol or hydrocarbon solvent such as ethanol, diethyl ether or hexane and the reaction is carried out at a temperature from about 10°C to about 50°C, preferably at about room temperature.
  • a compound having a formula identical to formula VI except that R 25 is replaced by a hydroxy group is reacted with a compound of the formula or wherein Y 4 is hydrogen or (C 1 -C 5 )alkyl, in the presence of an organic base.
  • Bases that may be used include (C 4 -C 10 )alkylamines and dialkylamines, pyridine, quinoline and isoquinoline.
  • Suitable solvents include ether and hydrocarbon solvents such as diethyl ether, methylene chloride, tetrahydrofuran and chloroform. Reaction temperatures may range from about 0°C to about 50°C, and are preferably between about 0°C and about room temperature.
  • reaction produces a compound of the formula VI wherein R 25 is or , which is then reacted with the salt of formula XXII to produce the desired compound of formula VI.
  • This reaction is generally conducted in an ether, halocarbon or hydrocarbon solvent (e.g., diethyl ether, hexane, methylene chloride or chloroform) at a temperature from about room temperature to about 60°C, preferably at about room temperature.
  • this reaction is carried out in an ethereal, halocarbon or hydrocarbon solvent at temperatures from about -70°C to about 0°C.
  • it is carried out in ether, tetrahydrofuran, dioxane, hexane, pentane, methylene chloride or chloroform at a temperature from about -30°C to about 0°C.
  • Such compounds can be prepared by reacting an isocyanate of the formula
  • This reaction is usually conducted at a temperature ranging from about ambient temperature to about 150°C, preferably from about ambient temperature to about 100°C.
  • the starting material of the formula XXIII can be prepared from the compound using standard methods described in the scientific literature.
  • pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5.0 atmospheres are generally acceptable, and ambient pressure, i.e., about one atmosphere, is preferred as a matter of convenience. Reaction times also are not critical unless otherwise indicated. Reaction times from about 0.5 hours to about 3 hours are generally acceptable, though longer reaction times (e.g., 24 or 48 hours) may be employed as a matter of convenience. Reaction times are monitored by thin layer chromatography.
  • the pharmaceutically acceptable acid addition salts of the compounds of the formulae I and VI that are basic in nature may be prepared in a conventional manner by treating a solution or suspension of the free base of formula I or VI with about one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration and recrystallization techniques are employed in isolating the salts.
  • the pharmaceutically acceptable base addition salts of compounds of the formulae I and VI that are acidic in nature may be formed with pharmaceutically acceptable cations by conventional methods.
  • these salts may be readily prepared by treating the compound of formula I or VI with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure.
  • a lower alkyl alcohol solution of the compound of formula I or VI may be mixed with an alkoxide of the desired metal and the solution subsequently evaporated to dryness.
  • the active compounds and compositions of this invention may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally, parenterally and topically.
  • compounds of the formula I and their pharmaceutically acceptable salts will be administered orally or parenterally at dosages between about 0.1 and about 50 mg/kg body weight of the subject to be treated per day, preferably from about 0.1 to 15 mg/kg, in single or divided doses.
  • mutual prodrugs of compounds of the formula I and aldose reductase inhibitors will generally be administered orally or parenterally at dosages between about 5 and about 100 mg/kg body weight of the subject to be treated per day, preferably from about 5 to about 25 mg/kg, in single or divided doses.
  • compositions containing both a compound of the formula I and an aldose reductase inhibitor will generally be administered orally or parenterally at dosages between about 1 and about 100 mg of each active component (i.e., the compound of formula I and the aldose reductase inhibitor) per kg body weight of the subject to be treated per day, preferably from about 1 to about 25 mg/kg.
  • each active component i.e., the compound of formula I and the aldose reductase inhibitor
  • the person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • the active compounds and compositions of this invention may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses.
  • suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • the pharmaceutical compositions formed by combining the active compounds of this invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like.
  • These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols.
  • the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
  • solutions of the active compounds and compositions of this invention in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solutions may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • the active compounds and compositions of this invention may be more particularly employed in the preparation of ophthalmic solutions.
  • Such ophthalmic solutions are of principal interest for the treatment of diabetic cataracts by topical administration.
  • the active compounds and compositions of this invention are administered to the eye in the form of an ophthalmic preparation prepared in accordance with conventional pharmaceutical practice.
  • the ophthalmic preparation will contain a compound of the formula I, a mutual prodrug of a compound of the formula I and an aldose reductase inhibitor, or a pharmaceutically acceptable salt of such compound of formula I or prodrug, in a concentration from about 0.01 to about 1% by weight, preferably from about 0.05 to about 0.5%, in a pharmaceutically acceptable solution, suspension or ointment.
  • each active ingredient will be present in an amount from about 0.005 to about 1% by weight, preferably from about 0.005 to about 0.25%, in a pharmaceutically acceptable solution, suspension or ointment.
  • Sorbitol in erythrocytes and nerves was measured by a modification of the method of R. S. Clements et al. (Science, 166: 1007-8, 1969). Aliquots of tissue extracts were added to an assay system which had final concentrations of reagents of 0.033 M glycine, pH 9.4, 800 ⁇ M ß-nicotine adenine dinucleotide, and 4 units/ml of sorbitol dehydrogenase. After incubation for 30 minutes at room temperature, sample fluorescence was determined on a fluorescence spectrophotometer with excitation at 366 nm and emission at 452 nm. After subtracting appropriate blanks, the amount of sorbitol in each sample was determined from a linear regression of sorbitol standards processed in the same manner as the tissue extracts.
  • Fructose was determined by a modification of the method described by M.
  • SDH activity was measured by a modification of the method described by U.
  • IC 50 values of 4-[4-(N,N-dimethylsulfamoyl)-piperazino]-2-methylpyrimidine and the title compounds of Example 1-4 are set forth in Table I below.
  • the IC 50 values indicate the concentration at which fifty percent inhibition of sorbitol dehydrogenase in vitro was observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to methods of inhibiting sorbitol dehydrogenase, lowering fructose levels, and treating or preventing diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic microangiopathy or diabetic macroangiopathy in a mammal using pyrimidine derivatives of formula (I) wherein R?1, R2, R3, R4 and R5¿ are defined as below, and to pharmaceutical compositions containing such derivatives. It also relates to certain novel substituted pyrimidines having the above formula. It also relates to mutual prodrugs of compounds of above formula (I) and aldose reductase inhibiting compounds, and to pharmaceutical compositions comprising a compound of above formula (I) and an aldose reductase inhibitor.

Description

SUBSTITUTED PYRIMIDINES FOR CONTROL OF DIABETIC COMPLICATIONS
Background of the Invention
This application is a continuation in part of United States Patent Application Serial No. 07/952,222, filed September 28, 1992.
The present invention relates to novel pyrimidine derivatives and to the use of such derivatives and related compounds to inhibit sorbitol dehydrogenase, lower fructose levels, or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to pharmaceutical compositions containing such pyrimidine derivatives and related compounds.
S. Ao et al., Metabolism. 40, 77-87 (1991 ) have shown that significant functional improvement in the nerves of diabetic rats (based on nerve conduction velocity) occurs when nerve fructose levels are pharmacologically lowered, and that such improvement correlates more closely with the lowering of nerve fructose than the lowering of nerve sorbitol. Similar results were reported by N. E. Cameron and M. A. Cotter, Diabetic Medicine. 8, Suppl. 1 , 35A-36A (1991). In both of these cases, lowering of nerve fructose was achieved using relatively high does of aldose reductase inhibitors, which inhibit the formation of sorbitol, a precursor of fructose, from glucose via the enzyme aldose reductase.
We have found that pyrimidine derivatives of the formula I, as defined below, and their pharmaceutically acceptable salts, lower fructose levels in the tissues of mammals affected by diabetes (e.g., nerve, kidney and retina tissue) and are useful in the treatment and prevention of the diabetic complications referred to above. These compounds, or their metabolites in vivo, are inhibitors of the enzyme sorbitol dehydrogenase, which catalyzes the oxidation of sorbitol to fructose.
Summary Cf the Invention
The present invention also relates to the use of substituted pyrimidines of the formula I, as defined below, to treat or prevent diabetic complications in mammals, and to pharmaceutical compositions containing such pyrimidines.
Compounds of the formula I are those having the formula
Figure imgf000004_0002
wherein R1 is hydrogen, CF3, (C1-C6)alkyl, (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyl-SO-(C1-C6)alkyl, (C1-C6)alkyl-SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl, dihydroxy-(C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, aryl selected from phenyl and naphthyl, aryl-(C1-C6)alkyl wherein the aryl moiety is selected from phenyl and naphthyl, (C1-C6)alkoxycarbonylaryl wherein the aryl moiety is selected from phenyl and naphthyl, aryl-(C1-C6)alkyl wherein the aryl moiety is selected from phenyl and naphthyl, aryl-(C1-C6)alkyloxy wherein the aryl moiety is selected from phenyl and naphthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, and benzothienyl; heteroaryl-(C1-C6)alkyl wherein heteroaryl is defined as above, or heteroaryl-(C1-C6)alkyloxy wherein heteroaryl is defined as above, and wherein said aryl and heteroaryl groups, the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl and aryl-(C1-C6)alkyloxy and the heteroaryl moiety of said heteroaryl-(C1-C6)alkyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl;
or R1 is a group of the formula
Figure imgf000004_0001
wherein the dotted line represents an optional double bond, W, Q and Z are independently selected from hydrogen, (C1-C6)alkyl and trifluoromethyl, phenyl, furyl, triazolyl, thiazolyl and thienyl, wherein said phenyl, furyl, triazotyl, thiazolyl and thienyl may optionally be substituted with one or more substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl and hydroxy; or R1 is a group of the formula
Figure imgf000005_0002
, wherein R6 is hydrogen, (C1-C6)alkyl, aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl and benzothienyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkoxy, -S- (C1-C6)alkyl, -SO-(C1-C6)aIkyl and -SO2-(C1-C6)alkyl; or R1 is a group of the formula
Figure imgf000005_0001
, wherein R7 is aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, benzothienyl and quinolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyi, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and trifluoromethyl, and Y is hydrogen, benzyl, acetyl, benzoyl, aryl selected from phenyl and naphthyl, heteroaryl selected from furyl, thienyl, thiazolyl and oxazolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl and -SO2-(C1-C6)alkyl;
R2 and R3 are independently selected from hydrogen, (C1-C6)alkyl, phenyl and phenyl-(C1-C4)alkyl, wherein said phenyl and the phenyl moiety of said phenyl -(C1-C4)alkyl may optionally be substituted with one or more substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, chloro, bromo and trifluoromethyl;
or R2 and R3 form, together with the nitrogen to which they are attached, a cyclic group selected from azetidino, pyrrolidino, piperidino, piperazino and morpholino, wherein said cyclic group may optionally be substituted with from zero to two substituents, independently selected from (C1-C6)alkyl, -CONH2, -SO2NH2, N-(C1-C4)alkylsulfamoyl, N,N-di-(C1-C4)alkylsulfamoyl, (C1-C6)alkoxycarbonyl, N,N-di-(C1-C4)alkylcarbamoyl, N-(C1-C4)alkylcarbamoyl, N-phenylcarbamoyl, (C1-C6)alkylcarbonyl, phenylcarbonyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylsϋlf inyl , phenylsulfonyl, heteroarylsulfonyl and heteroarylcarbonyl, wherein the heteroaryl moieties of said heteroarylcarbonyl and heteroarylsulfonyl are selected from furyl, thienyl, thiazolyl, and oxazolyl, and wherein the phenyl moieties of said phenylcarbonyl, N-phenylcarbamoyl, phenylcarbonyl and phenylsulfonyl may optionally be substituted with one or more substituents independently selected from (C1-C4)alkyl, (C1-C4)alkoxy, chloro, bromo, nitro, amino, cyano and trifluoromethyl;
R4 is hydrogen, chloro, bromo, cyano, nitro, trifluoromethyl, amino, (C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, phenyl, naphthyl or furyl, wherein said phenyl, naphthyl and furyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, - S- (C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy; and
R5 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, (C1-C6)hydroxyalkyl,
- S-(C1-C6)alkyl, -SO- (C1-C6)alkyl, -SO2-(C1-C6)alkyl, phenyl or furyl, wherein said phenyl and furyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy.
Several of the substituted pyrimidines of formula I, as well as processes for preparing them, are referred to in European Patent Application 470,616A2, published February 12, 1992 and European Patent Application 384.370A1 , published August 29, 1990. These references are incorporated herein by reference in their entirety.
More specifically, this invention relates to a pharmaceutical composition comprising a sorbitol dehydrogenase inhibiting effective amount of a compound of the formula I , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
This invention also relates to a method of inhibiting the enzyme sorbitol dehydrogenase in a mammal, including a human, comprising administering to said mammal a sorbitol dehydrogenase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.
This invention also relates to a pharmaceutical composition comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, and a pharmaceutically acceptable carrier.
This invention also relates to a method of lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.
This invention also relates to a pharmaceutical composition comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, and a pharmaceutically acceptable carrier.
This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
This invention also relates to those compounds of the formula I wherein R1 is
(C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyl-SO-(C1- C6)alkyl,(C1-C6)alkyl-SO2-(C1-C6)alkyl,dihydroxy-(C1-C6)alkyl, aryl, heteroaryl, heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy or heteroaryl-(C1-C6)alkyloxy, wherein said aryl and the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, and aryl-(C1-C6)alkyloxy are independently selected from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moieties of said heteroaryl-(C1-C6)alkyl and heteroaryl-(C1-C6)alkyloxy are independently selected from wherein the aryl moiety is selected from phenyl and naphthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl and benzothiazolyl, and wherein said aryl and heteroaryl and the aryl and heteroaryl moieties of said heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl,aryl-(C1-C6)alkyloxyandheteroaryl-(C1-C6)alkyloxymayoptionally be substituted with one or more substituents, preferably with one or two substituents, independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, - SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl;
or R1 is a group of the formula
Figure imgf000008_0001
wherein the dotted line represents an optional double bond, W, Q and Z are independently selected from hydrogen, (C1-C6)alkyl and trifluoromethyl, phenyl, furyl, triazolyl, thiazolyl and thienyl, wherein said phenyl, furyl, triazolyl, thiazolyl and thienyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl and hydroxy; or R1 is a group of the formula
Figure imgf000008_0002
, wherein R6 is hydrogen, (C1-C6)alkyl, aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl and benzothienyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl and -SO2-(C1-C6)alkyl;
or R1 is a group of the formula
Figure imgf000008_0003
, wherein R7 is aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, benzothienyl and quinolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2- (C1-C6)alkyl and trifluoromethyl, and Y is hydrogen, benzyl, acetyl, benzoyl, aryl selected from phenyl and naphthyl, heteroaryl selected from furyl, thienyl, thiazolyl and oxazolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl and -SO2-(C1-C6)alkyl. These novel compounds are hereinafter referred to, collectively, as compounds of the formula IA. This invention also relates to the pharmaceutically acceptable acid addition and base salts of the novel compounds of formula IA.
This invention also relates to mutual prodrugs of a compound of the formula I and an aldose reductase inhibiting compound.
This invention also relates to compounds of the formula
Figure imgf000009_0003
wherein R25 is
Figure imgf000009_0001
or O2NH2CO2S-R26
Figure imgf000009_0002
, and R26 is aryl selected from phenyl and naphthyl, wherein said aryl may optionally be substituted with one or more substituents, preferably with one or two substituents, independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1- C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl;
R2 and R3 are independently selected from hydrogen, (C1-C6)alkyl, phenyl and phenyl-(C1-C4)alkyl, wherein said phenyl and the phenyl moiety of said phenyl -(C1-C4)alkyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, chloro, bromo and trifluoromethyl;
or R2 and R3 form, together with the nitrogen to which they are attached, a cyclic group selected from azetidino, pyrrolidino, piperidino, piperazino and morpholino, wherein said cyclic group may optionally be substituted with from zero to two substituents independently selected from (C1-C6)alkyl, -CONH2, -SO2NH2, N-(C1- C4)alkylsulfamoyl, N,N-di-(C1-C4)alkylsulfamoyl, (C1-C6)alkoxycarbonyl, N,N-di-(C1- C4)alkylcarbamoyl, N-(C1-C4)-alkylcarbamoyl, N-phenylcarbamoyl, (C1- C6)alkylcarbonyl, phenylcarbonyl, (C1-C6)alkylsulfonyl-, (C1-C6 )alkylsulfinyl, phenylsulfonyl, heteroarylsulfonyl and heteroarylcarbonyl, wherein the heteroaryl moieties of said heteroarylcarbonyl and heteroarylsulfonyl are selected from furyl, thienyl, thiazolyl and oxazolyl, and wherein the phenyl moieties of said phenylcarbonyl, N-phenylcarbamoyl, phenylcarbonyl and phenylsulfonyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from (C1-C4)alkyl, (C1-C4)alkoxy, chloro, bromo, nitro, amino, cyano and trifluoromethyl;
R4 is hydrogen, chloro, bromo, cyano, nitro, trifluoromethyl, amino, (C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, phenyl, naphthyl or furyl, wherein said phenyl, naphthyl and furyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy;
R5 is hydrogen, (C1-C6)alkyI, (C1-C6)alkoxy, trifluoromethyl, (C1-C6)hydroxyalkyl, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, phenyl or furyl, wherein said phenyl and furyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy;
R8 is hydrogen or R7;
R7 is aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, benzothienyl and quinolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and trifluoromethyl, and Y is hydrogen, benzyl, acetyl, benzoyl, aryl selected from phenyl and naphthyl, or heteroaryl selected from furyl, thienyl, thiazolyl and oxazolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl and -SO2-(C1-C6)alkyl; Y2 is
Figure imgf000011_0001
Figure imgf000011_0002
, or Y2 is absent (i.e., the carbon to which R8 is attached tly bonded to );
Y4 is hydrogen or(C1-C5)alkyl; and
Y3 is selected from the following groups:
Figure imgf000012_0001
Figure imgf000012_0002
Figure imgf000012_0004
Figure imgf000012_0003
Figure imgf000012_0005
Figure imgf000012_0006
Figure imgf000012_0008
Figure imgf000012_0007
and
Figure imgf000013_0001
wherein A is CH2, CH2CH2, CH(CH3) or
Figure imgf000013_0002
;
B is oxygen or sulfur;
R9 is selected from phenyl, benzothiazol-2-yl, benzoxazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl, thiazolopyridin-2-yl, oxazolopyridin-2-yl, 3-phenyl-1 ,2,4-oxadiazol-5-yl, and 5-phenyl-1 ,2,4-oxadiazol-3-yl, and R9 may optionally be substituted with from one to three substituents independently selected from fluorine, chlorine, bromine, methyl, methylthio, methoxy, hydroxy and trifluoromethyl;
R10 and R11 are independently selected from hydrogen, fluorine, chlorine, bromine, (C1-C4)alkyl, (C1-C4)alkylthio, (C1-C4)alkoxy and trifluoromethyl;
or R10 and R11 together, with the carbons to which they are attached, form a group of the formula
, o,r
Figure imgf000013_0003
Figure imgf000013_0004
Figure imgf000013_0005
wherein p is 1 or 2; D and E are independently selected from -CH2-, oxygen and sulfur, except that D and E cannot both be oxygen and cannot both be sulfur; R12 and R13 are independently selected from hydrogen, fluorine, chlorine, bromine, (C1-C4)alkyl, (C1-C4)alkylthio, (C1-C4)alkoxy and trifluoromethyl; and F and G are independently selected from -CH- and nitrogen;
R12 and R13 are independently selected from hydrogen, fluorine, chlorine, bromine, (C1-C4)alkyl, (C1-C4)alkylthio, (C1-C4)alkoxy and trifluoromethyl; K is oxygen, sulfur, SO or SO2;
R14 is hydrogen, fluoro, chloro, bromo, methyl, nitro, cyano, methanesulfonyl or benzoyl;
R15 is hydrogen, fluoro, chloro, bromo, carboxy, (C1-C3)alkyl, (C1-C3)alkoxy or benzyloxy;
R16 is hydrogen, fluoro, chloro, bromo or (C1-C3)alkyl;
or R15 and R16, together with the carbon atoms to which they are attached, form a 7,8-benzo ring;
R17 is (C1-C4)alkyl, trifluoromethyl or (CH2)nAr, wherein n is 0, 1 or 2 and Ar is phenyl optionally substituted with one or two substituents independently selected from methoxy, fluoro, chloro and bromo;
R18 is hydrogen, methyl or ethyl;
or R17 and R18, together with the carbon to which they are attached, form a saturated 4 or 5 membered carbocyclic spiro ring; and
R19 is hydrogen or methyl;
with the proviso that: (a) when K is other than oxygen, R14 is fluoro, chloro, cyano or nitro, and R15 and R16 do not form a 7,8-benzo ring; and (b) when K is other than oxygen or R17 is other than methyl, ethyl or trifluoromethyl, both R18 and R19 are hydrogen; and (c) when Y3 is a group of the formula XIVA, R9 is benzothiazol-2-yl or substituted benzothiazol-2-yl;
and the pharmaceutically acceptable salts of such compounds.
Compounds of the formula
Figure imgf000014_0002
wherein Y3 is one of the above groups VII to XIV are known aldose reductase inhibitors. Compounds of the formula VI wherein
R25 is
Figure imgf000014_0001
are conjugates and mutual prodrugs of such aldose reductase inhibitors and the pharmaceutically active compounds of the formula I wherein R1 is - CH2OH, -CHR7OH or hydroxy-(C1-C6)alkyl. As mutual prodrugs, they are expected to release in vivo both pharmaceutically active agents - a compound of the formula I wherein R1 is -CH2OH, -CHR7OH or hydroxy-(C1-C6)alkyl and an aldose reductase inhibitor of the formula
Figure imgf000015_0001
.
Compounds of the formula O2N-CH2-SO2-R26-NH2, wherein R26 is defined as above, are also known aldose reductase inhibitors. Compounds of the formula VI wherein R25 is O2NH2CO2S-R26
Figure imgf000015_0002
are conjugates and mutual prodrugs of such aldose reductase inhibitors and the pharmaceutically active compounds of the formula
I wherein R1 is -CH2OH, -CHR7OH or hydroxy-(C1-C6)alkyl. As mutual prodrugs, they are expected to release in vivo both pharmaceutically active agents - a compound of the formula I wherein R1 is -CH2OH, -CHR7OH or hydroxy-(C1-C6)alkyl and an aldose reductase inhibitor of the formula O2N-CH2-SO2-R26-NH2.
Preferred embodiments of this invention include those compounds of the formula VI, and pharmaceutically acceptable salts thereof, wherein R25 is
Figure imgf000015_0003
, Y2 is not absent and: (a) Y3 is a group of the formula VII, R9 is phenyl, substituted phenyl, benzothiazol-2-yl or benzoxazol-2-yl, A is -CH2-, and R10 and R11 are either both methyl or they form, together with the carbons to which they are attached, a group of the formula
O R ;
Figure imgf000015_0004
Figure imgf000015_0005
(b) Y3 is a group of the formula VIII, R9 is phenyl, substituted phenyl, benzothiazol-2-yl or benzoxazol-2-yl, A is -CH2-, and R12 and R13 are independently selected from bromo and chloro; (c) Y3 is a group of the formula IX and each of R12 and R13 is hydrogen; (d) Y3 is a group of the formula X and R12 and R13 are independently selected from (C1-C6)alkoxy and trifluoromethyl; (e) Y3 is a group of the formula XI and R12 and R13 are independently selected from (C1-C6)alkyl; (f) Y3 is a group of the formula XII, R9 is phenyl, substituted phenyl or benzothiazol-2-yl, A is -CH2- and R12 and R13 are independently selected from chloro and bromo; or (g) Y3 is a group of the formula XIII, each of R14 and R19 is hydrogen, each of R17 and R18 is methyl, R15 is 6-chloro or 6-fluoro and R16 is 7-chloro or 7-fluoro.
Preferred embodiments of this invention also include those compounds of the formula VI that are mutual prodrugs of a compound of the formula I and an aldose reductase inhibitor of the formula
Figure imgf000016_0001
, wherein such aldose reductase inhibitor is selected from:
3,4-dihydro-4-oxo-3-[[(5-trifluoromethyl)-2-benzothiazolyl]-methyl]-1 -phthalazineacetic acid;
3,4-dihydro-4-oxo-3-[[(5,7-difluoro)-2-benzothiazolyl]-methyl]-1 -phthalazineacetic acid;
3,4-dihydro-4-oxo-3-[[(5,7-dichloro)-2-benzothiazolyl]-methyl]-1-phthalazineacetic acid;
2-[4-(4,5,7-trifluorobenzothiazoI-2-yl)methyl-3,4-dihydro-3-oxo-2H-1 ,4-benzothiazin-2-yl] acetic acid;
[4,5-dimethyl-6-oxo-1 -(5-trifluoromethyl-benzothiazolylmethyl)-1 ,6-dihydro-pyridazin-3-yl]-acetic acid;
[4,5-dimethyl-6-oxo-1-(5,7-difluoro-benzothiazolylmethyl)-1 ,6-dihydro-pyridazin-3-yl]-acetic acid;
[4,5-dimethyl-6-oxo-1-(5,7-dichlorobenzothiazol-2-ylmethyl)-1 ,6-dihydro-pyridazin-3-yl]-acetic acid;
4-oxo-3[[(5-trifluoromethyl)-benzothiazol-2-ylmethyl]3,4,5,6,7,8-hexahydro-phthalazin-1-yl]-acetic acid;
4-oxo-3-[[(5,7-difluoro)-benzothiazol-2-ylmethyl]-3,4,5,6,7,8-hexahydro-phthalazin-1-yl]-acetic acid;
4-oxo-3-[[(5,7-dichloro)-benzothiazol-2-ylmethyl]-3,4,5,6,7,8-hexahydro-phthalazin-1-yl]-acetic acid;
N-[[5-trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine;
3,4-dihydro-4-oxo-3-(4-bromo-2-fiuorobenzyl)-1-phthalazineacetic acid;
(Z)-3-(carboxymethyl-[(2E)-methylphenylpropenylidene]-rhodanine;
2-[3-(4-bromo-2-fluorobenzyl)-7-chloro-1 ,2,3,4-tetrahydro-2,4-dioxo-1 -quinazolinyl]-acetic acid; 2R,4R-6,7-dichloro-4-hydroxy-2-methylchroman-4-acetic acid;
2R,4R-7-chloro-6-fluoro-4-hydroxy-2-methylchroman-4-acetic acid; and
3,4-dihydro-2,8-diisopropyl-3-oxo-2H-1 ,4-benzoxazine-4-acetic acid.
This invention also relates to a pharmaceutical composition comprising: (a) an amount of a mutual prodrug of a compound of the formula I and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug, effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes; and (b) a pharmaceutically acceptable carrier.
This invention also relates to a method of lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a mutual prodrug of a compound of the formula I and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug.
This invention also relates to a pharmaceutical composition comprising: (a) an amount of a mutual prodrug of a compound of the formula I and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human; and (b) a pharmaceutically acceptable carrier.
This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a mutual prodrug of a compound of the formula I and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug, effective in treating or preventing such complication.
This invention relates to a pharmaceutical composition comprising an amount of a compound of the formula VI , or a pharmaceutically acceptable salt thereof, effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, and a pharmaceutically acceptable carrier.
This invention also relates to a method of lowering thelevel of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula VI, or a pharmaceutically acceptable salt thereof.
This invention also relates to a pharmaceutical composition comprising an amount of a compound of the formula VI, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, and a pharmaceutically acceptable carrier.
This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula VI, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
Compounds of the formulae XV-XIX, which are defined below, and their pharmaceutically acceptable salts, are also known compounds that exhibit activity as aldose reductase inhibitors. These compounds have the following structures:
,
Figure imgf000019_0002
Figure imgf000019_0003
,
Figure imgf000019_0005
Figure imgf000019_0004
and
MSO2CH2NO2
XIX
wherein L is oxygen, CH2 sulfur or
Figure imgf000019_0001
;
J is hydrogen, methyl or -CNH2;
G is CH or N;
R20 and R21 are independently selected from hydrogen, fluorine, chlorine, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl or -SO2-(C1-C6)alkyl;
M is phenyl, naphthyl or a heteroaryl group selected from furan, morpholine, pyrrolidine, tetrahydroisoquinoline, thiophene, thiazole, oxazole, benzofuran, benzothiophene, benzothiazole, benzoxazole and indole, wherein said phenyl, naphthyl and heteroaryl groups may optionally be substituted with up to three substituents independently selected from chloro, fluoro, bromo, cyano, nitro, hydroxy, carboxy, amino (C1-C6)alkylamino, (C1-C6)dialkylamino, (C1-C6)alkanoylamino, (C1-C6)alkanoyl, (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C6)alkenyloxy, fluoro-(C1-C6)alkyl, (C1-C6)alkoxy, fluoro-(C1-C4)alkoxy, (C1-C6)hydroxyalkyI, carbamoyl, (C1-C7)alkylcarbamoyl, (C1-C7)dialkylcarbamoyl, sulfamoyl, (C1-C6)alkysulfamoyl, (C1-C6)dialkylsulfamoyl, (C1-C6)alkoxycarbonyl,(C1-C4)alkylenedioxy,(C1-C6)alkanesulfonamido,-S-(C1-C6)alkyl,-SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, phenyl, phenoxy, benzyloxy, benzyloxycarbonyl, benzamido, and benzenesulfonamido, and wherein said phenyl and the phenyl moieties of said phenoxy, benzyloxy, benzyloxycarbonyl, benzamido and benzenesulfonamido may optionally be substituted with a substituent selected from chlorine, fluorine, (C1-C4)alkyl (C1-C4)alkoxy and
Figure imgf000020_0002
wherein Y5 is oxygen or sulfur, or Y5 is absent (i.e., the phenyl ring is bonded to the carbon to which R22 and R23 are attached), and R22 and R23 are independently selected from hydrogen and (C1-C4)alkyl, and the phenyl moiety to which the -NHCOC(R22)(R23)- Y5- sidechain is attached may optionally be substituted with from one to three substituents independently selected from hydrogen, halo, trifluoromethyl, nitro, cyano, (C1-C4)alkyl, (C1-C4)alkoxy and (C1-C4)alkanoyl, or any adjacent pair of substituents may form, together with the carbons to which they are attached, a benzo ring which may optionally be substituted with a substituent independently selected from halo, (C1- C4)alkyl and (C1-C4)alkoxy; with the proviso that: (a) when J is
Figure imgf000020_0001
, G is CH and L is oxygen; and (b) M is not 2-carboxyphenyl.
This invention also relates to a pharmaceutical composition comprising: (a) an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetics; (b) an amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes and (c) a pharmaceutically acceptable carrier.
This invention also relates to a method of lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, in combination with a fructose lowering effective amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof.
This invention also relates to a pharmaceutical composition comprising: (a) an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human; (b) an amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy or diabetic microangiopathy or macroangiopathy in a mammal, including a human; and (c) a pharmaceutically acceptable carrier.
This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication, in combination with an amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
This invention also relates to a pharmaceutical composition comprising: (a) an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetics; (b) an amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes and (c) a pharmaceutically acceptable carrier.
This invention also relates to a method of lowering the level of fructose in one or more of the tissues of a mammal, including a human, that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, in combination with a fructose lowering effective amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, or a pharmaceutically acceptable salt thereof.
This invention also relates to a pharmaceutical composition comprising: (a) an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human; (b) an amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy or diabetic microangiopathy or macroangiopathy in a mammal, including a human; and (c) a pharmaceutically acceptable carrier.
This invention also relates to a method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication, in combination with an amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
Preferred embodiments of this invention include those pharmaceutical compositions and methods set forth above, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed is a compound wherein R1 is (C1-C6)hydroxyalkyI, (C1-C6)alkoxy, imidazolyl, furyl, pyrazolyl, tetrahydrofuryl, thienyl or triazolyl, or R1 is Y-O-CH-R7 wherein R7 is benzothiazolyl, furyl, imidazolyl, pyrazolyl, thienyl, triazolyl, (C1-C6)alkyl or trifluoromethyl, and Y is hydrogen or (C1-C6)alkyl, and R2 and R3 form, together with the nitrogen to which they are attached, a group of the formula
Figure imgf000023_0004
wherein X is carbon or -SO- and R24 is amino, (C1-C6)alkylamino, di-(C1-C6)alkylamino or pyridyl.
Particularly preferred embodiments of this invention are those pharmaceutical compositions and methods referred to above, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed is a compound wherein R1 is (C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, furyl, triazolyl, or tetrahydrofuryl, or
R1 is
Figure imgf000023_0002
wherein R7 is benzothiazolyl, furyl, thiazolyl, thienyl or trifluoromethyl, and Y is hydrogen or (C1-C6)alkyl, each of R4 and R5 is hydrogen, and R2 and R3, together with the nitrogen to which they are attached, form a group of the formula
Figure imgf000023_0003
wherein R27 and R28 are, independently, methyl or ethyl.
Other particularly preferred embodiments of this invention are those pharmaceutical compositions and methods referred to above, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed is a compound wherein R1 is (C1-C6)hydroxyalkyl, furyl or triazolyl, or R1 is
Figure imgf000023_0001
wherein R7 is furyl, thienyl or trifluoromethyl and Y is hydrogen, each of R4 and R5 is hydrogen, and R2 and R3, together with the nitrogen to which they are attached, form a group of the formula
Figure imgf000024_0001
wherein R27 and R28 are, independently, hydrogen, methyl or ethyl.
Preferred embodiments of this invention also include the pharmaceutical compositions and methods set forth above, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed is selected from:
4-[4-(N-methylsulfamoyl)-piperazino]-2-methylpyrimidine;
4-[4-(N-sulfamoyl)-piperazino]-2-methylpyrimidine;
4-[4-(N,N-dimethylsulfamoyI)-piperazino]-2-methylpyrimidine;
4-[4-(N-methylsulfamoyl)-piperizino]-2-hydroxymethylpyrimidine;
4-[4-(N-sulfamoyl)-piperizino]-2-hydroxymethylpyrimidine; and
4-[4-(N,N-dimethylsulfamoyl)-piperizino]-2-hydroxymethyipyrimidine.
Preferred embodiments of this invention also include those pharmaceutical compositions and methods set forth above that comprise or employ a composition comprising an aldose reductase inhibitor selected from:
(4-amino-2,6-dimethylphylsulfonyl)nitromethane;
N,N-diisopropyl-N'-[3,5-dimethyl-4-(nitromethylsulfonyl)phenyl]oxamide;
N-[3,5-dimethyl-4-(nitromethylsulfonyl)phenyl]-2-(piperidino)glyoxamide;
[2,6-dimethyl-4-(phenylacetamido)phenylsulfonyl]nitromethane;
[2,6-dimethyl-4-(2-phenoxyacetamido)phenylsulfonyl]nitromethane;
[2,6-dimethyl-4-(2-(3-methylphenoxyacetamido)phenyl)sulfonyl]nitromethane;
[2,6-dimethyl-4-(2-(3-chlorophenoxyacetamido)phenyl)sulfonyl]nitromethane;
[2,6-dimethyl-1-((2,4,6-trimethylphenyl)acetamido)phenylsulfonyI]nitromethane;
2,6-dimethyl-4-((2-methylphenyl)acetamido)phenylsulfonyl nitromethane;
2,6-dimethyl-4-((2-fluorophenyl)acetamido)phenylsulfonyl nitromethane;
2-(nitromethylsulfonyl)thiophene;
2-chloro-5-(nitromethylsulfonyl)thiophene;
N-(nitromethylsulfonyl)morpholine;
N-(nitromethylsulfonyl)piperidine;
N-(nitromethylsulfonyl)indoline;
d-6-fluoro-spiro(chroman-4,4'-imidazolidine)-2',5'-dione; 2-fluoro-spiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione;
2,7-difluoro-spiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione;
2,7'-difluoro-5-methoxy-spiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione;
7-fluoro-spiro(5H-indenol[1 ,2-b]pyridine-5,3'-pyrrolidine)2,5'-dione;
d-cis-6'-chloro-2',3,-dihydro-2'-methyl-spiro-(imidazolidine-4,4,-4'H-pyrano(2,3-b)pyridine)-2,5-dione;
spiro[imidazolidine-4,5'(6H)-quinoline]2,5-dione-3'-chloro-7',8'-dihydro-7'-methyl-, (5'S-cis); and
(2S,4S)-6-fluoro-2',5'-dioxospiro(chroman-4,4'-imidazolidine)-2-carboxamide. "A sorbitol dehydrogenase inhibiting effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof," as used herein, refers to an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that exhibits sorbitol dehydrogenase inhibiting activity, or an amount of such compound or salt that yields a metabolite in vivo that exhibits sorbitol dehydrogenase inhibiting activity.
The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.
The term "alkoxy", as used herein, includes O-alkyl groups wherein "alkyl" is defined as above.
The term "one or more substituents," as used herein, includes from one to the maximum number of substituents possible based on the number of available bonding sites.
The acids that may be used to prepare pharmaceutically acceptable acid addition salts of those compounds of formulae I and VI that are basic in nature are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate,ethanesulfonate,benzene-sulfonate,p-toluenesulfonateandpamoate [i.e., 1 ,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formulae I and VI that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
Description of the Drawings
Figure 1 illustrates the dose dependent lowering of erythrocyte fructose by 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 1 as "Compound 1") in diabetic rats.
Figure 2 illustrates the dose dependent elevation of erythrocyte sorbitol by 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methyIpyrimidine (referred to in Figure 2 as "Compound 1") in diabetic rats.
Figure 3 illustrates the dose dependent lowering of nerve fructose by 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 3 as "Compound 1") in diabetic rats.
Figure 4 illustrates the dose dependent elevation of nerve sorbitol by 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 4 as "Compound 1") in diabetic rats.
Figure 5 illustrates the dose dependent in vitro inhibition of sorbitol dehydrogenase by sera from rats dosed with 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 5 as "Compound 1 ").
Figure 6 illustrates the dose dependent in vitro inhibition of sorbitol dehydrogenase by urinefrom rats dosed with 4-[4-(N,N-dimethylsulfamoyl)piperizino]-2-methylpyrimidine (referred to in Figure 6 as "Compound 1 ").
Detailed Description of the Invention
Many of the substituted pyrimidines of the formula I are known compounds. These may be prepared from commercially available or known starting materials by the procedures set forth in European Patent Application 470616A2, published February 12, 1992 and European Patent Application 384,370A1 , published August 29, 1990.
Compounds of the formula XV may be prepared as described in United States Patent 4,130,714, which issued to Reinhard Sarges on December 19, 1978, United States Patent 5,066,659 which issued to Christopher A. Lipinski on November 19, 1991 , United States Patent 4,566,670, which issued to Christopher A. Lipinski on December 3, 1985, United States Patent 4,980,357, which issued to Goldstein et al. on December 25, 1990, United States Patent 4,540,704, which issued to Ueda et al. on September 10, 1985, and United States Patent 4,985,573, which issued to Kurono et al. on January 15, 1991. Compounds of the formula XVI may be prepared as described in United States Patents 4,436,745 and 4,438,272, which issued to Billie M. York, Jr. on March 13, 1984 and March 20, 1984, respectively. All of the foregoing documents are incorporated herein by reference in their entirety.
Compounds of the formulae VII and VIII may be prepared as described in United States Patent 5,039,672, which issued to Eggler et al. on August 13, 1991. Compounds of the formula XIX may be prepared as described in European Patent Applications EP 304190, EP 408713, EP 409449, EP 469887 and EP 469888, which were published, respectively, on February 22, 1989, January 23, 1991 , January 30, 1991 , February 5, 1992 and February 5, 1992, United States Patent 5,110,808, which issued to Brittain et al. on May 5, 1992, United States Patent 5,102,905, which issued to Brown et aL on
April 7, 1992, and United States Patent 5,096,918, which issued to Keith B. Mallion on
March 17, 1992. All of the foregoing documents are incorporated herein by reference in their entirety.
Compounds of the formula
Figure imgf000027_0002
, wherein Y3 is a group of the formula VII, as defined above, may be prepared as described in United States Patent 4,251 ,528, which issued to Brittain et al. on February 17, 1981 , United States Patent 4,996,204, which issued to Mylari et al. on February 26, 1991 , United States Patent 4,939,140, which issued to Larsen et al. on July 3, 1990, PCT Patent Application PCT/US 92/01603, which was filed on March 9, 1992, European Patent Application EP 436307, which was published on July 10, 1991 , and French Patent Application FR 2647676A1 , which was published on December 7, 1990. Compounds of the formula
Figure imgf000027_0001
, wherein Y3 is a group of the formula IX, as defined above, may be prepared as described in United States Patent 4,464,382, United States Patent 4,791 ,126 and United States Patent 4,831 ,045, which issued to Tanouchi et al. on, respectively, August 7, 1984, December 13, 1988 and May 16, 1989. All of the foregoing documents are incorporated herein by reference in their entirety.
Compounds of the formula
Figure imgf000028_0001
wherein Y3 is a group of the formula X, as defined above, may be prepared as described in United States Patent 4,391 ,825, which issued to Bellini et al. on July 5, 1983, and in United States Patent 4,568,693, United
States Patent 4,600,724 and United States Patent 4,705,882, which issued to Sestanj et al. on, respectively, February 4, 1986, July 15, 1986 and November 10, 1987.
Compounds of the formula
Figure imgf000028_0002
wherein Y3 is a group of the formula XI, as defined above, may be prepared as described in United States Patent 4,771 ,050, which issued to Meguro et al. on September 13, 1988. Compounds of the formula
Figure imgf000028_0003
wherein
Y3 is a group of the formula XII, as defined above, may be prepared as described by
Billon et al., Eur. J. Med. Chem., 25, 121 (1990). All of the foregoing documents are incorporated herein by reference in their entirety.
Compounds of the formula
Figure imgf000028_0004
wherein Y3 is a group of the formula XIII, as defined above, may be prepared as described in United States Patent 4,883,410, which issued to Christopher A. Lipinski on August 1 , 1989. Compounds of the formula
Figure imgf000028_0005
wherein Y3 is a group of the formula XIV, as defined above, may be prepared as described in European Patent Application 325375, which was published on July 26,
1989. Compounds of the formula
Figure imgf000028_0006
wherein Y3 is a group of the formula XIVA, as defined above, may be prepared as described in European Patent Application 492667A1 , which was published on July 1 , 1992. All of the foregoing documents are incorporated herein by reference in their entirety. Methods of preparing the various compounds and compositions of this invention are described below. Unless otherwise noted, in the reaction schemes and discussion that follow, R1 through R28, Q, W, Y, Y2, Y3, Y4, Y5, A, B, D, E, G, J, L, and M are defined as above.
Reaction schemes 1-3 below illustrate methods of preparing the novel compounds of the formula IA.
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
(R = optionally substituted aryl , optionally substituted heteroaryl , dihydroxy-(C1-C6)alkyl , (C1-C6)alkyl-S-(C1-C6)alkyl) , aryl-(C1-C6)alkyloxy wherein the aryl moiety is optionally substituted, aryl-(C1-C6)alkyl wherein the aryl moiety is optionally substituted, or heteroaryl-(C1-C6)alkyl wherein the heteroaryl moiety is optionally substituted) Referring to scheme 1 , compounds of the formula IA wherein R1 is
Figure imgf000033_0001
and R6 is hydrogen may be prepared by oxidizing the corresponding compounds wherein R1 is hydroxymethyl (-CH2OH). Oxidizing agents that may be used include chromic acid, silver oxide and activated manganese dioxide, with activated manganese dioxide being preferred. When chromic acid is used, the preferred solvent is water or an aqueous
(C3-C6)alkyl ketone (e.g., acetone) and the reaction temperature, which can range from about -78°C to about 25°C, is preferably from about -10°C to about 0°C. When silver oxide or activated manganese dioxide is used, the solvent is preferably a halocarbon solvent such as chloroform or methylene chloride, and the reaction temperature, which can range from about 0°C to about 100°C, is preferably between about 20°C and the reflux temperature of the solvent.
Compounds of the formula I A wherein R1 is
Figure imgf000033_0002
and R6 is other than hydrogen may be prepared by first reacting the corresponding compound wherein R1 is formyl (CHO) with an organolithium reagent of the formula R6Li or an appropriate Grignard reagent of the formula R6MgX wherein X is chloro, bromo or iodo, and then oxidizing the reaction product. The initial reaction with the Grignard or organolithium reagent is generally conducted in a hydrocarbon solvent such as n-pentane, n-hexane or n-heptane, at a temperature from about -70°C to about 0°C, preferably from about -70°C to about -20°C. The subsequent oxidation step may be carried out as described above for the oxidation of compounds wherein R1 is hydroxymethyl.
Compounds of the formula IA wherein R1 is
Figure imgf000033_0003
and Y is hydrogen may be prepared by reacting the corresponding compounds wherein R1 is
Figure imgf000033_0004
with an organolithium reagent of the formula R7Li or an appropriate Grignard reagent of the formula R7MgX, in the manner described above for preparing compounds of the formula
I wherein R1 is
Figure imgf000033_0005
and R6 is other than hydrogen. Treatment of the resulting compounds with an appropriate reagent of the formula Y-L, wherein Y is other than hydrogen and L is a leaving group, in the presence of a strong base yields the corresponding compounds wherein R1 is
Figure imgf000034_0005
and Y is other than hydrogen. Examples of bases that may be used are sodium hydride in dimethylformamide and a (C1-C6)alkyllithium in a hydrocarbon solvent (e.g. n-pentane or n-hexane). Suitable leaving groups include chloro, bromo, iodo and OSO2-(C1-C6) alkyl. The reaction temperature can range from about -20°C to about 100°C, and is preferably from about 0°C to about 60°C.
Scheme 2 illustrates the preparation of compounds of the formula IA wherein R1 is a group of the formula
Figure imgf000034_0004
Referring to scheme 2, such compounds may be prepared by reacting the corresponding compounds wherein R1 is
Figure imgf000034_0003
with a Wittig reagent of the formula
Figure imgf000034_0001
( Typically, this reaction is carried out in a nonprotic solvent such as dimethylformamide or a (C4-C6)alkylether, preferably tetrahydrofuran, at a temperature from about 0°C to about 100°C, preferably from about 25°C to about 100°C. The reactants in which R1 is
Figure imgf000034_0002
may be obtained by oxidation of the corresponding compounds wherein R1 is -CHOHW as described above for the oxidation of compounds wherein R1 is -CHOHR6. Similarly, those compounds wherein R1 is -CHOHW may be obtained by the procedure described above and depicted in scheme 1 for preparing the analogous compounds wherein R1 is -CHOHR6 or -CHOHR7.
Compounds of the formula IA wherein R1 is a group of the formula
Figure imgf000035_0001
may be formed by hydrogenation of the corresponding compounds wherein R1 is
Figure imgf000035_0002
in the presence of a metal containing catalyst. Suitable hydrogenation catalysts include palladium, platinum, nickel, platinum oxide and rhodium. The preferred catalyst for hydrogenation is platinum on carbon. The reaction temperature may range from about 10°C to about 50°C, with about 25°C being preferred. The hydrogenation is generally carried out at a pressure from about 1.5 to about 4 atmospheres, preferably at about
3.0 atmospheres, in a suitable inert solvent such as acetic acid or a lower alcohol, preferably methanol, with about a stoichiometric quantity of hydrogen chloride present.
Compounds of the formula I A wherein R1 is optionally substituted aryl, optionally substituted heteroaryl, dihydroxy-(C1-C6)alkyl or (C1-C6)alkyl-S-(C1-C6)alkyl may be prepared according to the reaction sequence illustrated and scheme 3. This reaction sequence is the same as that described in European Patent Applications 470616A2 and 384370A1 , referred to above, with the exception that a compound of the formula R1C=NHNH2, wherein R1 is defined as above, is used as a starting material. The conditions, reagents and catalysts, etc. used in the reactions of scheme 3 are set forth in detail in the foregoing patent applications, which, as indicated above, have been incorporated herein by reference in their entirety.
Referring to scheme 3, a compound of formula II or its acid addition salt is reacted with a compound of formula III to give a compound of formula IV. The reaction is generally conducted or an alcoholic solvent such as methanol, ethanol or tert-butanol, at a temperature from about 25°C to about 100°C, preferably from about 25°C to about 50°C. When an acid addition salt of a compound of formula II is employed, the reaction is generally conducted as above in the presence of an alkali metal or alkaline earth metal hydroxide (e.g., sodium, potassium, or calcium hydroxide) or an alkali metal alkoxide (e.g., sodium or potassium ethoxide or tert-butoxide) at temperatures ranging from about 10°C to about 80°C, preferably at temperatures between 30° and 60°C.
The compound of formula IV is converted into a pyrimidine derivative of the formula V by reacting it with an inorganic acid chloride, e.g., phosphorus oxychloride, thienyl chloride, phosphorus pentachloride or phosphorous trichloride. This reaction is usually conducted in an aromatic hydrocarbon solvent, e.g., benzene, toluene or xylene, at a temperature from about 30° to about 100°C. The preferred temperature range is between 30° and 60°C.
Reaction of the compound of formula V with the appropriate compound of formula NHR2R3 yields a compound of formula IA. Suitable solvents for this reaction include ethereal solvents such as ethyl ether, tetrahydrofuran, or dioxane and halocarbon solvents such as methylene chloride or chloroform. The reaction temperature may range from about 0°C to about 80°C. Preferably, the solvent is a halocarbon solvent and the temperature is between 0°C and 50°C.
Compounds of the formula IA wherein R1 is (C1-C6)alkoxycarbonyl-(C1-C6)alkyl may be prepared by reacting the corresponding compounds wherein R1 is hydroxy-(C1-C6)alkyl with the appropriate (C1-C6)alkanoic acid chloride in the presence of an organic base. Examples of suitable organic bases are (C4-C10)alkylamines and dialkylamines, pyridine, quinoline and isoquinoline. Generally, this reaction is carried out in another or halocarbon solvent such as diethyl ether, tetrahydrofuran (THF), methylene chloride or chloroform, at a temperature from about 0°C to about 50°C, preferably from about 0°C to about room temperature.
Compounds of the formula IA wherein R1 is (C1-C6)alkoxycarbonylaryl can be prepared in a similar manner, using the appropriate aroyl chloride in place of a (C1-C5)alkanoic acid chloride.
Compounds of the formula IA wherein R1 is (C1-C6)alkyl-SO-(C1-C6)alkyl may be prepared by oxidation of the corresponding compounds wherein R1 is (C1-C6)alkyl-S-(C1-C6)alkyl using methods well known to those skilled in the art. For example, these oxidations may be conducted using m-chloroperbenzoic acid as the oxidizing agent in a halocarbon solvent such as methylene chloride or chloroform, at a temperature from about -10°C to about 10°C, preferably about 0°C. Similarly, compounds of the formula IA wherein R1 is (C1-C6)alkyl-SO2-(C1-C6)alkyl may be prepared by oxidation of the corresponding compounds wherein R1 is (C1-C6)alkyl-SO-(C1-C6)alkyl using methods known in the art. Such oxidations may be conducted, for example, in the manner specified above, but at a temperature ranging from about room temperature to about
60°C, preferably at about the reflux temperature of the solvent.
Compounds of the formula VI can be prepared using methods that are well known in peptide chemistry. Some of these procedures are described below.
Compounds of the formula VI wherein R25 is
Figure imgf000037_0003
and Y2 is absent can be
prepared as follows. A compound of the formula
Figure imgf000037_0002
is first converted into
itscorresponding acid chloride,
Figure imgf000037_0001
, by reacting it with thionyl chloride in a suitable aromatic or halocarbon solvent (e.g., benzene, toluene, xylene, methylene chloride or chloroform), at a temperature from about 0°C to about 130°C, preferably from about 20°C to about 100°C. The acid chloride is then reacted with a compound having the following formula
Figure imgf000037_0004
to produce the corresponding compound of formula VI wherein Y2 is absent. This reaction is generally carried out in a halocarbon, aromatic hydrocarbon or ethereal solvent at a temperature from about 0°C to about 150°C, preferably from about 0°C and about 100°C. Preferred solvents include benzene, toluene, xylene, methylene chloride, chloroform, ether, tetrahydrofuran and dioxane. Alternatively, compounds of the formula VI wherein Y2 is absent can be prepared by reacting a compound of the formula
Figure imgf000038_0001
with a (C4-C8)alkylchloroformate in the presence of any organic base, and then adding a compound of the formula XX, as depicted and defined above, to the reaction mixture. Examples of bases that may be used are (C3-C6)alkylamines and aromatic amines such as pyridine, quinoline or isoquinoline. This reaction is typically conducted in a halocarbon solvent, preferably methylene chloride or chloroform, at a temperature from about -70°C to about 50°C, preferably from about -70°C to about 20°C.
The addition of the compound of formula XX is typically carried out at temperatures ranging from about -70°C to about 50°C, preferably from about -70°C and about 30°C.
Compounds for the formula VI wherein R25 is
Figure imgf000038_0002
and Y2 is
Figure imgf000038_0003
can be prepared by the following procedure. A compound of the formula XX, as depicted and defined above, is reacted with phosgene, to obtain a compound of the formula
Figure imgf000038_0004
This reaction is conducted in the presence of a base (e.g., a (C3-C10)alkylamine or an aromatic amine such as pyridine, quinoline or isoquinoline) at a temperature from about -70°C to about 0°C, preferably from about -30°C to about 0°C. Appropriate solvents include ethereal, halocarbon and (C5-C10) hydrocarbon solvents. Ether, dioxane, tetrahydrofuran, pentane, hexane, methylene chloride and chloroform are preferred.
The compound of formula XXI formed in the above reaction is then reacted with a compound of the formula
Figure imgf000038_0005
in the presence of a base (e.g., a (C3-C10)alkylamine or an aromatic amine such as pyridine, quinoline or isoquinoline). The reaction is generally conducted at a temperature ranging from about -20°C to about room temperature, preferably between about -10°C and about room temperature, in a halocarbon or ether solvent, preferably in methylene chloride or chloroform.
Compounds of the formula VI wherein R25 is
Figure imgf000039_0006
and Y2 is
Figure imgf000039_0008
- may be prepared in the following manner. First, a compound of the formula
Figure imgf000039_0007
is contacted with an Ameberlite® IRA-904 resin containing quaternary ammonium groups in the hydroxide form to yield a salt of the formula
Figure imgf000039_0004
Figure imgf000039_0005
(hereinafter referred to as a salt of the formula XXII). Usually, the compound of formula
Figure imgf000039_0003
is dissolved in a lower alcohol or hydrocarbon solvent such as ethanol, diethyl ether or hexane and the reaction is carried out at a temperature from about 10°C to about 50°C, preferably at about room temperature. Then, a compound having a formula identical to formula VI except that R25 is replaced by a hydroxy group is reacted with a compound of the formula
Figure imgf000039_0001
or
Figure imgf000039_0002
wherein Y4 is hydrogen or (C1-C5)alkyl, in the presence of an organic base. Bases that may be used include (C4-C10)alkylamines and dialkylamines, pyridine, quinoline and isoquinoline. Suitable solvents include ether and hydrocarbon solvents such as diethyl ether, methylene chloride, tetrahydrofuran and chloroform. Reaction temperatures may range from about 0°C to about 50°C, and are preferably between about 0°C and about room temperature.
The foregoing reaction produces a compound of the formula VI wherein R25 is
Figure imgf000039_0009
or
Figure imgf000039_0010
, which is then reacted with the salt of formula XXII to produce the desired compound of formula VI. This reaction is generally conducted in an ether, halocarbon or hydrocarbon solvent (e.g., diethyl ether, hexane, methylene chloride or chloroform) at a temperature from about room temperature to about 60°C, preferably at about room temperature.
Compounds of the formula VI wherein R25 is O2NH2CO2S-R26
Figure imgf000040_0001
may be prepared by reacting a compound of the formula
Figure imgf000040_0002
with a compound of the formula O2NCH2SO2-R26-NH2.
Typically, this reaction is carried out in an ethereal, halocarbon or hydrocarbon solvent at temperatures from about -70°C to about 0°C. Preferably, it is carried out in ether, tetrahydrofuran, dioxane, hexane, pentane, methylene chloride or chloroform at a temperature from about -30°C to about 0°C.
Alternatively, such compounds can be prepared by reacting an isocyanate of the formula
Figure imgf000040_0003
with a compound of the formula XX, as depicted and defined above. Suitable and preferred solvents for this reaction are similar to those specified for the preceding reaction. This reaction is usually conducted at a temperature ranging from about ambient temperature to about 150°C, preferably from about ambient temperature to about 100°C.
The starting material of the formula XXIII can be prepared from the compound
Figure imgf000041_0001
using standard methods described in the scientific literature.
In each of the reactions discussed or illustrated above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5.0 atmospheres are generally acceptable, and ambient pressure, i.e., about one atmosphere, is preferred as a matter of convenience. Reaction times also are not critical unless otherwise indicated. Reaction times from about 0.5 hours to about 3 hours are generally acceptable, though longer reaction times (e.g., 24 or 48 hours) may be employed as a matter of convenience. Reaction times are monitored by thin layer chromatography.
The pharmaceutically acceptable acid addition salts of the compounds of the formulae I and VI that are basic in nature may be prepared in a conventional manner by treating a solution or suspension of the free base of formula I or VI with about one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration and recrystallization techniques are employed in isolating the salts.
The pharmaceutically acceptable base addition salts of compounds of the formulae I and VI that are acidic in nature may be formed with pharmaceutically acceptable cations by conventional methods. Thus, these salts may be readily prepared by treating the compound of formula I or VI with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, a lower alkyl alcohol solution of the compound of formula I or VI may be mixed with an alkoxide of the desired metal and the solution subsequently evaporated to dryness.
Compounds of the formula I, the pharmaceutically acceptable salts of such compounds, mutual prodrugs of such compounds and aldose reductase inhibitors (including the mutual prodrugs of the formula VI), the pharmaceutically acceptable salts of such mutual prodrugs, and compositions comprising a compound of the formula I or a pharmaceutically acceptable salt thereof and an aldose reductase inhibitor or a pharmaceutically acceptable salt thereof (including compositions containing a compound of the formula I and a compound of the formula XV, XVI, XVII, XVIII or XIX) are hereinafter referred to, collectively, as "the active compounds and compositions of this invention".
The active compounds and compositions of this invention may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally, parenterally and topically. In general, compounds of the formula I and their pharmaceutically acceptable salts will be administered orally or parenterally at dosages between about 0.1 and about 50 mg/kg body weight of the subject to be treated per day, preferably from about 0.1 to 15 mg/kg, in single or divided doses. Mutual prodrugs of compounds of the formula I and aldose reductase inhibitors will generally be administered orally or parenterally at dosages between about 5 and about 100 mg/kg body weight of the subject to be treated per day, preferably from about 5 to about 25 mg/kg, in single or divided doses. Compositions containing both a compound of the formula I and an aldose reductase inhibitor will generally be administered orally or parenterally at dosages between about 1 and about 100 mg of each active component (i.e., the compound of formula I and the aldose reductase inhibitor) per kg body weight of the subject to be treated per day, preferably from about 1 to about 25 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
The active compounds and compositions of this invention may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the active compounds of this invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
For parenteral administration, solutions of the active compounds and compositions of this invention in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solutions may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
The active compounds and compositions of this invention may be more particularly employed in the preparation of ophthalmic solutions. Such ophthalmic solutions are of principal interest for the treatment of diabetic cataracts by topical administration. For the treatment of diabetic cataracts, the active compounds and compositions of this invention are administered to the eye in the form of an ophthalmic preparation prepared in accordance with conventional pharmaceutical practice. The ophthalmic preparation will contain a compound of the formula I, a mutual prodrug of a compound of the formula I and an aldose reductase inhibitor, or a pharmaceutically acceptable salt of such compound of formula I or prodrug, in a concentration from about 0.01 to about 1% by weight, preferably from about 0.05 to about 0.5%, in a pharmaceutically acceptable solution, suspension or ointment. In opthalmic preparations containing a combination of a compound of the formula I and an aldose reductase inhibitor, each active ingredient will be present in an amount from about 0.005 to about 1% by weight, preferably from about 0.005 to about 0.25%, in a pharmaceutically acceptable solution, suspension or ointment.
EXAMPLES
General Experimental Procedure
Male Sprague-Dawley rats (350-400 g) were used for these experiments.
Diabetes was induced in some of the rats by a tail vein injection of streptozocin, 85 mg/kg. Twenty-four hours later, 4 groups of diabetic rats were given a single dose of 4-[4-(N,N-dimethylsulfamoyl)-piperazino]-2-methylpyrimidine(10, 50, 100, or300 mg/kg) by oral gavage. Animals were sacrificed 4-6 hours after dosing and blood and sciatic nerves were harvested. Tissues and cells were extracted with 6% perchloric acid.
Sorbitol in erythrocytes and nerves was measured by a modification of the method of R. S. Clements et al. (Science, 166: 1007-8, 1969). Aliquots of tissue extracts were added to an assay system which had final concentrations of reagents of 0.033 M glycine, pH 9.4, 800 μM ß-nicotine adenine dinucleotide, and 4 units/ml of sorbitol dehydrogenase. After incubation for 30 minutes at room temperature, sample fluorescence was determined on a fluorescence spectrophotometer with excitation at 366 nm and emission at 452 nm. After subtracting appropriate blanks, the amount of sorbitol in each sample was determined from a linear regression of sorbitol standards processed in the same manner as the tissue extracts.
Fructose was determined by a modification of the method described by M.
Ameyama, Methods in Enzymoloqy, 89: 20-25 (1982). Resazurin was substituted for ferricyanide. Aliquots of tissue extracts were added to the assay system, which had final concentrations of reagents of 1.2 M citric acid, pH 4.5, 13 μM resazurin, 3.3 units/ml of fructose dehydrogenase and 0.068% Triton X-100. After incubation for 60 minutes at room temperature, sample fluorescence was determined on a fluorescence spectrophotometer with excitation at 560 nm and emission at 580 nm. After subtracting appropriate blanks, the amount of fructose in each sample was determined from a linear regression of fructose standards processed in the same manner as the tissue extracts.
SDH activity was measured by a modification of the method described by U.
Gerlach, Methodology of Enzymatic Analyses, edited by H. U: Bergmeyer, 3, 1 12-117 (1983). Aliquots of sera or urine were added to the assay system, which had final concentrations of reagents of 0.1 M potassium phosphate buffer, pH 7.4, 5 mM NAD, 20 mM sorbitol, and 0.7 units/ml of sorbitol dehydrogenase. After incubation for 10 minutes at room temperature, the average change in sample absorbance was determined at 340 nm. SDH activity was presented as milliOD340 units/minute (OD340 = optical density at 340 nm).
RESULTS
As shown in Figure 1 , 4-[4-(N,N-dimethylsulfamoyl)-piperazino]-2-methylpyrimidine ("Compound 1 ") dose dependently lowered erythrocyte (red blood cell -
"RBC") fructose in diabetic rats. It dose dependently raised erythrocyte sorbitol in diabetic rats (Figure 2). A similar lowering of fructose with an increase in sorbitol was seen in the sciatic nerve of diabetic rats (Figures 3 and 4).
This pattern of lowered fructose coupled with elevated sorbitol is consistent with that expected of an inhibitor of sorbitol dehydrogenase (SDH), the enzyme that converts sorbitol to fructose. However, when tested directly on sorbitol dehydrogenase in vitro, 4-[4-(N,N-dimethylsulfamoyl)-piperazino]-2-methylpyrimidine exhibited an IC50 value of 0.5mM. On the other hand, we discovered that sera from rats dosed with 4-[4-(N,N-dimethylsulfamoyl)-piperazino]-2-methylpyrimidine potently inhibited SDH in vitro in a dose dependent manner (Figure 5).
The urine of animals dosed with 4-[4-(N,N-dimethylsulfamoyl)-piperazino]-2-methylpyrimidine also potently inhibited SDH in vitro in a dose dependent manner (Figure 6). Comparison with results for the sera (Figure 5) shows that the urine was an even more potent source of SDH inhibitory activity, with strong inhibition of SDH found with as little as 0.5 μl of urine.
EXAMPLES 1 , 2 and 3
Example 1 : 4-[4-(N-methylsulfamoyl)-piperazino]-2-methylpyrimidine
Example 2: 4-[4-N-methylsulfamoyl)-piperazino]-2-hydroxy-methylpyrimidine
Example 3: 4[4-N-sulfamoyl)-piperazinol-2-methylpyrimidine
An aqueous suspension of 4-[4-(N,N-dimethylsulfamoyl)-piperazino]-2-methylpyrimidine ("Compound 1 "), prepared as described in European Patent Application 384.370A1 , was administered by oral gavage to male CD rats (350-430 g body weight) at a dose of 100 mg/kg. The rats were housed in appropriate cages and their urine (220 mL) was collected overnight. The urine was extracted with ethyl acetate (75 mL) and the resulting emulsion was filtered through a supercel pad and the filtrate was collected. The ethyl acetate layer was separated and the aqueous layer was extracted again (3 × 75 mL). The ethyl acetate extracts were combined and dried over anhydrous magnesium sulfate to obtain a crude oily residue (0.8 g). This residue was dissolved in 10 mL of a 9:1 mixture of methylene chloride and ethanol and chromatographed using a Chromatotron. The Chromatotron plate was eluted with a mixture of 19:1 of methylene chloride and ethanol and fractions were collected in 5 mL portions. Evaporation of the first 20 × 5 mL portions gave the title compound of Example 1 (6.9 mg): 1H NMR (DMSO, 500 MHz) δ 2.37 (s, 3H), 2.55 (d, J=7 Hz, 3H), 3.13 (m, 4H), 3.7 (m, 4H), 6.68 (d, J=8 Hz, 1 H), 7.72 (m, 1 H), 8.13 (d, J=8 Hz, 1 H). The next 20 × 5 mL portions yielded the title compound of Example 2 (24 mg): 1 H NMR (DMSO, 500 MHz) δ 2.48 (d, J=7 Hz, 3H), 3.1 (m, 4H), 3.58 (m, 4H), 4.36 (s, 2H), 6.1 (s, 1 H), 6.33 (d, J=8 Hz, 1 H), 6.5 (m, 1 H), 8.03 (d, J=8 Hz, 1 H). The last 20 × 5 mL portions gave the title compounds of Example 3 (15 mg): 1 H NMR (DMSO, 500 MHz) δ 2.34 (s, 3H), 3.04 (m, 4H), 3.65 (m, 4H), 6.35 (d, J=8 Hz, 1H), 7.93 (d, J=8 Hz, 1H).
EXAMPLE 4
4[4-(N,N-Dimethylsulfamoyl)piperizino]-2-hydroxymethylpyrimidine
The title compound was prepared as described in European Patent Application 470,616A2, published February 12, 1992.
The structures and IC50 values of 4-[4-(N,N-dimethylsulfamoyl)-piperazino]-2-methylpyrimidine and the title compounds of Example 1-4 are set forth in Table I below. The IC50 values indicate the concentration at which fifty percent inhibition of sorbitol dehydrogenase in vitro was observed.
Figure imgf000047_0001
EXAMPLE 5
4[4-(N,N-Dimethylsulfamoyl)piperizinolpyrimidine-2-ylmethyl-3,4-dihydro-4-oxo-3-[[(5-trifluoromethyl)-2-benzothiazolyl]-methyl]-1-phthalazine acetate
A solution of 3,4-dihydro-4-oxo-3-[[(5-trifluoromethyl)-2-benzothiazolyl]-methyl]-1-phthalazineacetic acid (839 mg, 2 mmol) in methylene chloride (10 mL) containing triethylamine (0.28 mL, 2 mmol) was added to a solution of isobutyl chloroformate (0.2 mL, 2 mmol) in methylene chloride (10 mL) at a temperature between -78° and -65°C. After 30 minutes, a solution of 4[4-(N,N-dimethylsulfamoyl)piperizino]-2-hydroxymethylpyrimidine in methylene chloride (5 mL) was added to the reaction mixture. The reaction was allowed to warm to room temperature, stirred for 2 hours and then quenched with water (20 mL). The methylene chloride layer was collected and was washed succesively with 5% sodium bicarbonate solution and water. The organic layer was dried, evaporated and the residue was chromatographed over silica gel. Elution with a solution of methylene chloride in methanol (95:5) and evaporation of the eluent gave the title compound (0.35 g). M.P. 97-99°C.

Claims

1. A compound of the formula
Figure imgf000049_0002
wherein R1 is (C1-C6)alkoxycarbonyl-(C1 -C6)alkyl , (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyl-SO-(C1-C6)alkyl, (C1-C6)alkyl-SO2-(C1-C6)alkyl, dihydroxy-(C1-C6)alkyl, aryl, heteroaryl, heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy or heteroaryl-(C1-C6)alkyloxy, wherein said aryl and the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, and aryl-(C1-C6)alkyloxy are independently selected from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moieties of said heteroaryl-(C1-C6)alkyl and heteroaryl-(C1-C6)alkyloxy are independently selected from wherein the aryl moiety is selected from phenyl and naphthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl and benzothiazolyl, and wherein said aryl and heteroaryl and the aryl and heteroaryl moieties of said heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl,aryl-(C1-C6)alkyloxyandheteroaryl-(C1-C6)alkyloxymayoptionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl;
or R1 is a group of the formula
Figure imgf000049_0001
wherein the dotted line represents an optional double bond, W, Q and Z are independently selected from hydrogen, (C1-C6)alkyl and trifluoromethyl, phenyl, furyl, triazolyl, thiazolyl and thienyl, wherein said phenyl, furyl, triazolyl, thiazolyl and thienyl may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl and hydroxy; or R1 is a group of the formula
Figure imgf000050_0002
, wherein R6 is hydrogen, (C1-C6)alkyl, aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl and benzothienyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkoxy, -S-(C1- C6)alkyl, -SO-(C1-C6)alkyl and -SO2-(C1-C6)alkyl;
or R1 is a group of the formula
Figure imgf000050_0001
, wherein R7 is aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, benzothienyl and quinolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and trifluoromethyl, and Y is hydrogen, benzyl, acetyl, benzoyl, aryl selected from phenyl and naphthyl, heteroaryl selected from furyl, thienyl, thiazolyl and oxazolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1- C6)alkyl and -SO2-(C1-C6)alkyl;
R2 and R3 are independently selected from hydrogen, (C1-C6)alkyl, phenyl and phenyl-(C1-C4)alkyl, wherein said phenyl and the phenyl moiety of said phenyl -(C1- C4)alkyl may optionally be substituted with one or more substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, chloro, bromo and trifluoromethyl;
or R2 and R3 form, together with the nitrogen to which they are attached, a cyclic group selected from azetidino, pyrrolidino, piperidino, piperazino and morpholino, wherein said cyclic group may optionally be substituted with from zero to two substituents, independently selected from (C1-C6)alkyl, -CONH2, -SO2NH2, N-(C1- C4)alkylsulfamoyl, N,N-di-(C1-C6)alkylsulfamoyl, (C1-C6)alkoxycarbonyl, N,N-di-(C1-C4)alkylcarbamoyl, N-(C1-C4)-alkylcarbamoyl, N-phenylcarbamoyl, (C1-C6)alkylcarbonyl, phenylcarbonyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfinyl, phenylsulfonyl, heteroarylsulfonyl and heteroarylcarbonyl, wherein the heteroaryl moieties of said heteroarylcarbonyl and heteroarylsulfonyl are selected from furyl, thienyl, thiazolyl, and oxazolyl, and wherein the phenyl moieties of said phenylcarbonyl, N-phenylcarbamoyl, phenylcarbonyl and phenylsulfonyl may optionally be substituted with one or more substituents, independently selected from (C1-C4)alkyl, (C1-C4)alkoxy, chloro, bromo, nitro, amino, cyano and trifluoromethyl;
R4 is hydrogen, chloro, bromo, cyano, nitro, trifluoromethyl, amino, (C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, phenyl, naphthyl or furyl, wherein said phenyl, naphthyl and furyl may optionally be substituted with one or more substituents, independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy; and
R5 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, (C1-C6)hydroxyalkyl,
-S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, phenyl or furyl, wherein said phenyl and furyl may optionally be substituted with one or more substituents, independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy;
or a pharmaceutically acceptable salt of such compound.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a compound of the formula
Figure imgf000051_0001
wherein R1 is hydrogen, CF3, (C1-C6)alkyl, (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyl-SO-(C1-C6)alkyl, (C1-C6)alkyl-SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl, dihydroxy-(C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl- (C1-C6)alkyl, aryl selected from phenyl and naphthyl, aryl-(C1-C6)alkyl wherein the aryl moiety is selected from phenyl and naphthyl, (C1-C6)alkoxycarbonylaryl wherein the aryl moiety is selected from phenyl and naphthyl, aryl-(C1-C6)alkyl wherein the aryl moiety is selected from phenyl and naphthyl, aryl-(C1- C6)alkyloxy wherein the aryl moiety is selected from phenyl and napthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, and benzothienyl; heteroaryl-(C1- C6)alkyl wherein heteroaryl is defined as above, or heteroaryl-(C1-C6)alkyloxy wherein heteroaryl is defined as above, and wherein said aryl and heteroaryl groups, the aryl moieties of said aryl- (C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl and aryl-(C1-C6)alkyloxy and the heteroaryl moiety of said heteroaryl-(C1-C6)alkyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1- C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyI, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl;
or R1 is a group of the formula
Figure imgf000052_0001
wherein the dotted line represents an optional double bond, W, Q and Z are independently selected from hydrogen, (C1-C6)alkyl and trifluoromethyl, phenyl, furyl, triazolyl, thiazolyl and thienyl, wherein said phenyl, furyl, triazolyl, thiazolyl and thienyl may optionally be substituted with one or more substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl and hydroxy; or R1 is a group of the formula
Figure imgf000052_0002
, wherein R6 is hydrogen, (C1-C6)alkyl, aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl and benzothienyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl and -SO2-(C1-C6)alkyl; or R1 is a group of the formula
Figure imgf000052_0003
, wherein R7 is aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, benzothienyl and quinolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and trifluoromethyl, and Y is hydrogen, benzyl, acetyl, benzoyl, aryl selected from phenyl and naphthyl, heteroaryl selected from furyl, thienyl, thiazolyl and oxazolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl and -SO2-(C1-C6)alkyl;
R2 and R3 are independently selected from hydrogen, (C1-C6)alkyl, phenyl and phenyl-(C1-C4)alkyl, wherein said phenyl and the phenyl moiety of said phenyl -(C1-C4)alkyl may optionally be substituted with one or more substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, chloro, bromo and trifluoromethyl;
or R2 and R3 form, together with the nitrogen to which they are attached, a cyclic group selected from azetidino, pyrrolidino, piperidino, piperazino and morpholino, wherein said cyclic group may optionally be substituted with from zero to two substituents, independently selected from (C1-C6)alkyl, -CONH2, -SO2NH2, N-(C1-C4)alkylsulfamoyl, N,N-di-(C1-C4)alkylsulfamoyl, (C1-C6)alkoxycarbonyl, N,N-di-(C1-C4)alkylcarbamoyl, N-(C1-C4)alkylcarbamoyl, N-phenylcarbamoyl, (C1-C6)alkylcarbonyl, phenylcarbonyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfinyl, phenylsulfonyl, heteroarylsulfonyl and heteroarylcarbonyl, wherein the heteroaryl moieties of said heteroarylcarbonyl and heteroarylsulfonyl are selected from furyl, thienyl, thiazolyl, and oxazolyl, and wherein the phenyl moieties of said phenylcarbonyl, N-phenylcarbamoyl, phenylcarbonyl and phenylsulfonyl may optionally be substituted with one or more substituents independently selected from (C1-C4)alkyl, (C1-C4)alkoxy, chloro, bromo, nitro, amino, cyano and trifluoromethyl;
R4 is hydrogen, chloro, bromo, cyano, nitro, trifluoromethyl, amino, (C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, phenyl, naphthyl or furyl, wherein said phenyl, naphthyl and furyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, - S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy; and
R5 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, (C1-C6)hydroxyalkyl, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, phenyl or furyl, wherein said phenyl and furyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy;
or a pharmaceutically acceptable salt thereof, effective in (a) inhibiting the enzyme sorbitol dehydrogenase, (b) lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes, or (c) treating or preventing a diabetic complication in a mammal.
3. A pharmaceutical composition according to claim 2, wherein the compound of formula I is a compound wherein R1 is (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyl-SO-(C1-C6)alkyl, (C1-C6)alkyl-SO2-(C1-C6)alkyl, dihydroxy-(C1-C6)alkyl, aryl, heteroaryl, heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy or heteroaryl-(C1-C6)alkyloxy, wherein said aryl and the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, and aryl(C1-C6)alkyloxy are independently selected from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moieties of said heteroaryl-(C1-C6)alkyl and heteroaryl-(C1-C6)alkyloxy are independently selected from wherein the aryl moiety is selected from phenyl and naphthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl and benzothiazolyl, and wherein said aryl and heteroaryl and the aryl and heteroaryl moieties of said heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy and heteroaryl-(C1- C6)alkyloxy may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl.
4. A pharmaceutical composition according to claim 2, comprising an amount of said compound of the formula I that is effective in inhibiting the enzyme sorbitol dehydrogenase.
5. A pharmaceutical composition according to claim 2, comprising an amount of said compound of the formula I that is effective in lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes.
6. A pharmaceutical composition according to claim 2, comprising an amount of said compound of the formula I that is effective in treating or preventing a diabetic complication in a mammal.
7. A pharmaceutical composition according to claim 6, wherein said diabetic complication is diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic microangiopathy or diabetic macroangiopathy.
8. A method of: (a) inhibiting the enzyme sorbitol dehydrogenase in a mammal; (b) lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes; or (c) treating or preventing a diabetic complication in a mammal; comprising administering to said mammal an amount of a compound of the formula
Figure imgf000055_0001
wherein R1 is hydrogen, CF3, (C1-C6)aikyl, (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyl-SO-(C1-C6)alkyl, (C1-C6)alkyl-SO2- (C1-C6)alkyl, hydroxy-(C1-C6)alkyl, dihydroxy-(C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, aryl selected from phenyl and naphthyl, aryl-(C1-C6)alkyl wherein the aryl moiety is selected from phenyl and naphthyl, (C1-C6)alkoxycarbonylaryl wherein the aryl moiety is selected from phenyl and naphthyl, aryl-(C1-C6)alkyl wherein the aryl moiety is selected from phenyl and naphthyl, aryl-(C1-C6)alkyloxy wherein the aryl moiety is selected from phenyl and napthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, and benzothienyl; heteroaryl-(C1-C6)alkyl wherein heteroaryl is defined as above, or heteroaryl-(C1-C6)alkyloxy wherein heteroaryl is defined as above, and wherein said aryl and heteroaryl groups, the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl and aryl-(C1-C6)alkyloxy and the heteroaryl moiety of said heteroaryl-(C1-C6)alkyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1- C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl;
or R1 is a group of the formula
Figure imgf000056_0001
wherein the dotted line represents an optional double bond, W, Q and Z are independently selected from hydrogen, (C1-C6)alkyl and trifluoromethyl, phenyl, furyl, triazolyl, thiazolyl and thienyl, wherein said phenyl, furyl, triazolyl, thiazolyl and thienyl may optionally be substituted with one or more substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl and hydroxy; or R1 is a group of the formula
Figure imgf000056_0002
, wherein R6 is hydrogen, (C1-C6)alkyl, aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl and benzothienyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl and -SO2-(C1-C6)alkyl; or R1 is a group of the formula
Figure imgf000056_0003
, wherein R7 is aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, benzothienyl and quinolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl - SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and trifluoromethyl, and Y is hydrogen, benzyl, acetyl, benzoyl, aryl selected from phenyl and naphthyl, heteroaryl selected from furyl, thienyl, thiazolyl and oxazolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl and - SO2-(C1-C6)alkyl;
R2 and R3 are independently selected from hydrogen, (C1-C6)alkyl, phenyl and phenyl-(C1-C4)alkyl, wherein said phenyl and the phenyl moiety of said phenyl -(C1- C4)alkyl may optionally be substituted with one or more substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, chloro, bromo and trifluoromethyl; or R2 and R3 form, together with the nitrogen to which they are attached, a cyclic group selected from azetidino, pyrrolidino, piperidino, piperazino and morpholino, wherein said cyclic group may optionally be substituted with from zero to two substituents, independently selected from (C1-C6)alkyl, -CONH2, -SO2NH2, N-(C1-C4)alkylsulfamoyl, N,N-di-(C1-C4)alkylsulfamoyl, (C1-C6)alkoxycarbonyI, N,N-di-(C1-C4)alkylcarbamoyl, N-(C1-C4)alkylcarbamoyl, N-phenylcarbamoyl, (C1-C6)alkylcarbonyl, phenylcarbonyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfinyl, phenylsulfonyl, heteroarylsulfonyl and heteroarylcarbonyl, wherein the heteroaryl moieties of said heteroarylcarbonyl and heteroarylsulfonyl are selected from furyl, thienyl, thiazolyl, and oxazolyl, and wherein the phenyl moieties of said phenylcarbonyl, N-phenylcarbamoyl, phenylcarbonyl and phenylsulfonyl may optionally be substituted with one or more substituents independently selected from (C1-C4)alky!, (C1-C4)alkoxy, chloro, bromo, nitro, amino, cyano and trifluoromethyl;
R4 is hydrogen, chloro, bromo, cyano, nitro, trifluoromethyl, amino, (C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, phenyl, naphthyl or furyl, wherein said phenyl, naphthyl and furyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, - S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy; and
R5 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, (C1-C6)hydroxyalkyl, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, phenyl or furyl, wherein said phenyl and furyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy;
or a pharmaceutically acceptable salt thereof, effective in, respectively: (a) inhibiting the enzyme sorbitol dehydrogenase; (b) lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes; or (c) treating or preventing a diabetic complication.
9. A method according to claim 8, wherein the compound of formula I that is employed is a compound wherein R1 is (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkyl-S-(C1-C6)alkyl,(C1-C6)alkyl-SO-(C1-C8)alkyl,(C1-C6)alkyl-SO2-(C1-C6)alkyl,dihydroxy-(C1-C6)alkyl, aryl, heteroaryl, heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy or heteroaryl-(C1-C6)alkyloxy, wherein said aryl and the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, and aryl- (C1-C6)alkyloxy are independently selected from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moieties of said heteroaryl-(C1-C6)alkyl and heteroaryl-(C1-C6)alkyloxy are independently selected from wherein the aryl moiety is selected from phenyl and naphthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl and benzothiazolyl, and wherein said aryl and heteroaryl and the aryl and heteroaryl moieties of said heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy and heteroaryl-(C1-C6)alkyloxy may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl.
10. A method according to claim 8 of inhibiting sorbitol dehydrogenase in a mammal.
11. A method according to claim 8 of lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes.
12. A method according to claim 8 of treating or preventing a diabetic complication in a mammal.
13. A method according to claim 12, wherein said diabetic complication is diabetic neuropathy, a diabetic vascular disease, microangiopathy or diabetic macroangiopathy.
14. A pharmaceutical composition according to claim 2 in unit dosage form.
15. A pharmaceutical composition according to claim 2, in the form of a tablet suitable for oral administration.
16. A pharmaceutical composition according to claim 2, in the form of a solution suitable for parenteral administration.
17. A pharmaceutical composition according to claim 2, in the form of a solution suitable for ophthalmic administration.
18. A mutual prodrug of a compound according to claim 1 and an aldose reductase inhibiting compound.
19. A mutual prodrug of a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt thereof, and an aldose reductase inhibiting compound.
20. A compound of the formula
Figure imgf000059_0003
wherein R25 is
Figure imgf000059_0001
or O2NH2CO2S-R26
Figure imgf000059_0002
, and R26 is aryl selected from phenyl and naphthyl, wherein said aryl may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-Ce)alkyl, (C1-C6)alkoxy, -S- (C1-C6)alkyl,-SO-(C1-C6)alkyl, -SO2-(C1-C6)alkylf hydroxy-(C1-C6)alkylandtrifluoromethyl;
R2 and R3 are independently selected from hydrogen, (C1-C6)alkyl, phenyl and phenyl-(C1-C4)alkyl, wherein said phenyl and the phenyl moiety of said phenyl -(C1-C4)alkyl may optionally be substituted with one or more substituents independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, chloro, bromo and trifluoromethyl;
or R2 and R3 form, together with the nitrogen to which they are attached, a cyclic group selected from azetidino, pyrrolidino, piperidino, piperazino and morpholino, wherein said cyclic group may optionally be substituted with from zero to two substituents independently selected from (C1-C6)alkyl, -CONH2, -SO2NH2, N-(C1-C4)alkylsulfamoyl, N,N-di-(C1-C4)alkylsulfamoyl, (C1-C6)alkoxycarbonyl, N,N-di-(C1-C4)alkylcarbamoyl, N-(C1-C4)-alkylcarbamoyl, N-phenylcarbamoyl, (C1- C6)alkylcarbonyl, phenylcarbonyl, (C1-C6 )alkylsulfonyl, (C1-C6)alkylsulfinyl, phenylsulfonyl, heteroarylsulfonyl and heteroarylcarbonyl, wherein the heteroaryl moieties of said heteroarylcarbonyl and heteroarylsulfonyl are selected from furyl, thienyl, thiazolyl and oxazolyl, and wherein the phenyl moieties of said phenylcarbonyl, N-phenylcarbamoyl, phenylcarbonyl and phenylsulfonyl may optionally be substituted with one or more substituents independently selected from (C1-C4)alkyl, (C1-C4)alkoxy, chloro, bromo, nitro, amino, cyano and trifluoromethyl;
R4 is hydrogen, chloro, bromo, cyano, nitro, trifluoromethyl, amino, (C1-C6)alkyl, (C1-C6)hydroxyalkyl, (C1-C6)alkoxy, phenyl, naphthyl or furyl, wherein said phenyl, naphthyl and furyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, - S-(C1-C6)alkyl, -SO- (C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy; R5 is hydrogen, (C1-C8)alkyl, (C1-C6)alkoxy, trifluoromethyl, (C1-C6)hydroxyalkyl,
-S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, phenyl or furyl, wherein said phenyl and furyl may optionally be substituted with one or more substituents independently selected from chloro, bromo, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl and hydroxy;
R8 is hydrogen or R7;
R7 is aryl selected from phenyl and naphthyl, or heteroaryl selected from pyridyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, benzothiazolyl, benzofuranyl, benzothienyl and quinolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-Cg)alkyl, -SO2-(C1- C6)alkyl and trifluoromethyl, and Y is hydrogen, benzyl, acetyl, benzoyl, aryl selected from phenyl and naphthyl, or heteroaryl selected from furyl, thienyl, thiazolyl and oxazolyl, wherein said aryl and heteroaryl groups may optionally be substituted with one or more substituents independently selected from chloro, bromo, nitro, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-Ce)alkyl and -SO2-(C1-C6)alkyl;
Figure imgf000060_0001
,
Figure imgf000060_0002
or Y2 is absent (i.e., the carbon to which R8 is attached is directly bonded to
Figure imgf000060_0003
)
Y4 is hydrogen or (C1-C6)alkyl; and
Y3 is selected from the following groups:
Figure imgf000061_0006
Figure imgf000061_0001
Figure imgf000061_0004
Figure imgf000061_0005
Figure imgf000061_0003
Figure imgf000061_0002
Figure imgf000061_0008
and
Figure imgf000062_0001
wherein A is CH2, CH2CH2, CH(CH3) or
Figure imgf000062_0002
B is oxygen or sulfur;
R9 is selected from phenyl, benzothiazol-2-yI, benzoxazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl, thiazolopyridin-2-yl, oxazolopyridin-2-yl, 3-phenyl-1 ,2,4-oxadiazol-5-yl, and 5-phenyl-1 ,2,4-oxadiazol-3-yl, and R9 may optionally be substituted with from one to three substituents independently selected from fluorine, chlorine, bromine, methyl, methylthio, methoxy, hydroxy and trifluoromethyl;
R10 and R11 are independently selected from hydrogen, fluorine, chlorine, bromine, (C1-C4)alkyl, (C1-C4)alkylthio, (C1-C4)alkoxy and trifluoromethyl;
or R10 and R11 together, with the carbons to which they are attached, form a group of the formula
Figure imgf000062_0003
wherein p is 1 or 2; D and E are independently selected from -CH2-, oxygen and sulfur, except that D and E cannot both be oxygen and cannot both be sulfur; R12 and R13 are independently selected from hydrogen, fluorine, chlorine, bromine, (C1-C4)alkyl, (C1-C4)alkylthio, (C1-C4)alkoxy and trifluoromethyl; and F and G are independently selected from -CH- and nitrogen;
R12 and R13 are independently selected from hydrogen, fluorine, chlorine, bromine, (C1-C4)alkyl, (C1-C4)alkylthio, (C1-C4)alkoxy and trifluoromethyl; K is oxygen, sulfur, SO or SO2;
R14 is hydrogen, fluoro, chloro, bromo, methyl, nitro, cyano, methanesulfonyl or benzoyl;
R15 is hydrogen, fluoro, chloro, bromo, carboxy, (C1-C3)alkyl, (C1-C3)alkoxy or benzyloxy;
R16 is hydrogen, fluoro, chloro, bromo or (C1-C3)alkyl;
or R15 and R16, together with the carbon atoms to which they are attached, form a 7,8-benzo ring;
R17 is (C1-C4)alkyl, trifluoromethyl or (CH2)nAr, wherein n is 0, 1 or 2 and Ar is phenyl optionally substituted with one or two substituents independently selected from methoxy, fluoro, chloro and bromo;
R18 is hydrogen, methyl or ethyl;
or R17 and R18, together with the carbon to which they are attached, form a saturated 4 or 5 membered carbocyclic spiro ring; and
R19 is hydrogen or methyl;
with the proviso that: (a) when K is other than oxygen, R14 is fluoro, chloro, cyano or nitro, and R15 and R16 do not form a 7,8-benzo ring; (b) when K is other than oxygen or R17 is other than methyl, ethyl or trifluoromethyl, both R18 and R19 are hydrogen; and (c) when Y3 is a group of the formula XIVA, R9 is benzothiazol-2-yl or substituted benzothiazol-2-yl;
or a pharmaceutically acceptable salt of such compound.
21. A compound according to claim 20 wherein R25 is
Figure imgf000063_0001
, Y2 is not absent and: (a) Y3 is a group of the formula VII, R9 is phenyl, substituted phenyl, benzothiazol-2-yl or benzoxazol-2-yl, A is -CH2-, and R10 and R11 are either both methyl or they form, together with the carbons to which they are attached, a group of the formula
O R ;
Figure imgf000063_0003
Figure imgf000063_0002
(b) Y3 is a group of the formula VIII, R9 is phenyl, substituted phenyl, benzothiazol-2-yl or benzoxazol-2-yl, A is -CH2-, and R12 and R13 are independently selected from bromo and chloro; (c) Y3 is a group of the formula IX and each of R12 and R13 is hydrogen; (d) Y3 is a group of the formula X and R12 and R13 are independently selected from (C1-C6)alkoxy and trifluoromethyl; (e) Y3 is a group of the formula XI and R12 and R13 are independently selected from (C1-C6)alkyl; (f) Y3 is a group of the formula XII, R9 is phenyl, substituted phenyl or benzothiazol-2-yl, A is -CH2- and R12 and R13 are independently selected from chloro and bromo; or (g) Y3 is a group of the formula XIII, each of R14 and R19 is hydrogen, each of R17 and R18 is methyl, R15 is 6-chloro or 6-fluoro and R16 is 7-chloro or 7-fluoro.
22. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a mutual prodrug of a compound according to claim 1 and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug, that is effective in (a) inhibiting the enzyme sorbitol dehydrogenase, (b) lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes, or (c) treating or preventing a diabetic complication in a mammal.
23. A method of: (a) inhibiting the enzyme sorbitol dehydrogenase in a mammal; (b) lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes; or (c) treating or preventing a diabetic complication in a mammal; comprising administering to said mammal an amount of a mutual prodrug of a compound according to claim 1 and an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt of such a prodrug, that is effective in, respectively: (a) inhibiting the enzyme sorbitol dehydrogenase, (b) lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes, or (c) treating or preventing a diabetic complication in a mammal.
24. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a mutual prodrug of an aldose reductase inhibiting compound and a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt of such a prodrug, that is effective in (a) inhibiting the enzyme sorbitol dehydrogenase, (b) lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes, or (c) treating or preventing a diabetic complication in a mammal.
25. A method of: (a) inhibiting the enzyme sorbitol dehydrogenase in a mammal; (b) lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes; or (c) treating or preventing a diabetic complication in a mammal; comprising administering to said mammal an amount of a mutual prodrug of an aldose reductase inhibiting compound and a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt of such a prodrug, that is effective in, respectively: (a) inhibiting the enzyme sorbitol dehydrogenase, (b) lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes, or (c) treating or preventing a diabetic complication in a mammal.
26. A pharmaceutical composition comprising: (a) an amount of a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal, that are affected by diabetics; (b) an amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes; and (c) a pharmaceutically acceptable carrier.
27. A method of lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt thereof, in combination with a fructose lowering effective amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof.
28. A pharmaceutical composition comprising (a) an amount of a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal; (b) an amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy or diabetic microangiopathy or macroangiopathy in a mammal; and (c) a pharmaceutically acceptable carrier.
29. A method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, comprising administering to said mammal an amount of a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication, in combination with an amount of an aldose reductase inhibiting compound, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
30. A pharmaceutical composition comprising: (a) an amount of a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetics; (b) an amount of a compound of the formula
wherein L is oxygen, CH2 sulfur or
Figure imgf000067_0001
J is hydrogen, methyl or
Figure imgf000067_0002
;
G is CH or N;
R20 and R21 are independently selected from hydrogen, fluorine, chlorine, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl or -SO2-(C1-C6)alkyl;
M is phenyl, naphthyl or a heteroaryl group selected from furan, morpholine, pyrrolidine, tetrahydroisoquinoline, thiophene, thiazole, oxazole, benzofuran, benzothiophene, benzothiazole, benzoxazole and indole, wherein said phenyl, naphthyl and heteroaryl groups may optionally be substituted with up to three substituents independently selected from chloro, fluoro, bromo, cyano, nitro, hydroxy, carboxy, amino (C1-C6)alkylamino, (C1-C6)dialkylamino, (C1-C6)alkanoylamino, (C1-C6)alkanoyl, (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C6)alkenyloxy, fluoro-(C1-C6)alkyl, (C1-C6)alkoxy, fluoro-(C1-C4)alkoxy, (C1-C6) hydroxyalkyl, carbamoyl, (C1-C7)alkylcarbamoyl, (C1- C7)dialkylcarbamoyl, sulfamoyl, (C1-C6)alkysulfamoyl, (C1-C6)dialkylsulfamoyl, (C1- C6)alkoxycarbonyl, (C1-C4)alkylenedioxy, (C1-C6)alkanesulfonamido, -S-(C1-C4)alkyl, -SO- (C1-C6)alkyl, -SO2-(C1-C6)alkyl, phenyl, phenoxy, benzyloxy, benzyloxycarbonyl, benzamido, and benzenesulfonamido, and wherein said phenyl and the phenyl moieties of said phenoxy, benzyloxy, benzyloxycarbonyl, benzamido and benzenesulfonamido may optionally be substituted with a substituent selected from chlorine, fluorine, (C1- C4)alkyl (C1-C4)alkoxy and
Figure imgf000067_0003
wherein Y5 is oxygen or sulfur, or Y5 is absent (i.e., the phenyl ring is bonded to the carbon to which R22 and R23 are attached), and R22 and R23 are independently selected from hydrogen and (C1-C4)alkyl, and the phenyl moiety to which the -NHCOC(R22)(R23)-Y5- sidechain is attached may optionally be substituted with from one to three substituents independently selected from hydrogen, halo, trifluoromethyl, nitro, cyano, M is phenyl, naphthyl or a heteroaryl group selected from furan, morpholine, pyrrolidine, tetrahydroisoquinoline, thiophene, thiazole, oxazole, benzofuran, benzothiophene, benzothiazole, benzoxazole and indole, wherein said phenyl, naphthyl and heteroaryl groups may optionally be substituted with up to three substituents independently selected from chloro, fluoro, bromo, cyano, nitro, hydroxy, carboxy, amino (C1-C6)alkylamino, (C1-C6)dialkylamino, (C1-C6)alkanoylamino, (C1-C6)alkanoyl, (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C6)alkenyloxy, fluoro-(C1-C6)alkyl, (C1-C6)alkoxy, fluoro-(C1-C4) alkoxy, (C1-C6)hydroxyalkyl, carbamoyl, (C1-C 7)alkylcarbamoyl, (C1-C7)dialkylcarbamoyl, sulfamoyl, (C1-C6)alkysulfamoyl, (C1-C6)dialkylsulfamoyl, (C1-C6)alkoxycarbonyl,(C1-C4)alkylenedioxy,(C1-C8)alkanesulfonamido,-S-(C1-C6)alkyl,-SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, phenyl, phenoxy, benzyloxy, benzyloxycarbonyl, benzamido, and benzenesulfonamido, and wherein said phenyl and the phenyl moieties of said phenoxy, benzyloxy, benzyloxycarbonyl, benzamido and benzenesulfonamido may optionally be substituted with a substituent selected from chlorine, fluorine, (C1-C4)alkyl (C1-C4)alkoxy and
Figure imgf000068_0001
wherein Y5 is oxygen or sulfur, or Y5 is absent (i.e., the phenyl ring is bonded to the carbon to which R22 and R23 are attached), and R22 and R23 are independently selected from hydrogen and (C1-C4)alkyl, and the phenyl moiety to which the -NHCOC(R22)(R23)-Y5- sidechain is attached may optionally be substituted with from one to three substituents independently selected from hydrogen, halo, trifluoromethyl, nitro, cyano,(C1-C4)alkyl, (C1-C4)alkoxy and (C1-C4)alkanoyl, or any adjacent pair of substituents may form, together with the carbons to which they are attached, a benzo ring which may optionally be substituted with a substituent independently selected from halo, (C1-C4)alkyl and (C1-C4)alkoxy;
with the proviso that: (a) when J is
Figure imgf000068_0002
, G is CH and L is oxygen; and (b) M is not 2-carboxyphenyl; or a pharmaceutically acceptable salt thereof, that is effective in lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes; and (c) a pharmaceutically acceptable carrier.
31. A method of lowering the level of fructose in one or more of the tissues of a mammal that are affected by diabetes, comprising administering to said mammal a fructose lowering effective amount of a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt thereof, in combination with a fructose lowering effective amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, as defined in claim 30, or a pharmaceutically acceptable salt thereof.
32. A pharmaceutical composition comprising: (a) an amount of a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal; (b) an amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, as defined in claim 30, or a pharmaceutically acceptable salt thereof, effective in treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy or diabetic microangiopathy or macroangiopathy in a mammal; and (c) a pharmaceutically acceptable carrier.
33. A method of treating or preventing a diabetic complication such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, or diabetic microangiopathy or macroangiopathy in a mammal, comprising administering to said mammal an amount of a compound of the formula I, as defined in claim 2, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication, in combination with an amount of a compound of the formula XV, XVI, XVII, XVIII or XIX, as defined in claim 30, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such complication.
34. A pharmaceutical composition according to claim 30, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed is a compound wherein R1 is (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyl-SO-(C1-C6)alkyl, (C1-C6)alkyl-SO2-(C1-C6)alkyl, dihydroxy-(C1-C6)alkyl, aryl, heteroaryl, heteroaryl-(C1-C6)alkyl, aryl-(C1-C6 )alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy or heteroaryl-(C1-C6)alkyloxy, wherein said aryl and the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, and aryl- (C1-C6)alkyloxy are independently selected from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moieties of said heteroaryl-(C1-C6)aIkyl and heteroaryl-(C1-C6)alkyloxy are independently selected from wherein the aryl moiety is selected from phenyl and naphthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl and benzothiazolyl, and wherein said aryl and heteroaryl and the aryl and heteroaryl moieties of said heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy and heteroaryl-(C1-C6)alkyloxy may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl.
35. A method according to claim 31 , wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed, is a compound wherein R1 is (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyl-SO-(C1- C6)alkyl,(C1-C6)alkyl-SO2-(C1-C6)alkyl,dihydroxy-(C1-C6)alkyl, aryl, heteroaryl, heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy or heteroaryl-(C1-C6)alkyloxy, wherein said aryl and the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, and aryl-(C1-C6)alkyloxy are independently selected from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moieties of said heteroaryl-(C1-C6)alkyl and heteroaryl-(C1-C6)alkyloxy are independently selected from wherein the aryl moiety is selected from phenyl and naphthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl and benzothiazolyl, and wherein said aryl and heteroaryl and the aryl and heteroaryl moieties of said heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl,aryl-(C1-C6)alkyloxyandheteroaryl-(C1-C6)alkyloxymayoptionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl.
36. A pharmaceutical composition according to claim 32, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed, is a compound wherein R1 is (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyI-SO-(C1-C6)alkyl, (C1-C6)alkyl-SO2-(C1-C6)alkyl, dihydroxy-(C1-C6)alkyl, aryl, heteroaryl, heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy or heteroaryl-(C1-C6)alkyloxy, wherein said aryl and the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, and aryl-(C1-C6)alkyloxy are independently selected from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moieties of said heteroaryl-(C1-C6)alkyl and heteroaryl-(C1-C6)alkyloxy are independently selected from wherein the aryl moiety is selected from phenyl and naphthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl and benzothiazolyl, and wherein said aryl and heteroaryl and the aryl and heteroaryl moieties of said heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy and heteroaryl-(C1-C6)alkyloxy may optionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl and trifluoromethyl.
37. A method according to claim 33, wherein the compound of formula I, or pharmaceutically acceptable salt thereof, that is employed, is a compound wherein R1 is (C1-C6)alkoxycarbonyl-(C1-C6)alkyl, (C1-C6)alkyl-S-(C1-C6)alkyl, (C1-C6)alkyl-SO-(C1-C6)alkyl,(C1-C6)alkyl-SO2-(C1-C6)alkyl,dihydroxy-(C1-C6)alkyl, aryl, heteroaryl, heteroaryl(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, aryl-(C1-C6)alkyloxy or heteroaryl-(C1-C6)alkyloxy, wherein said aryl and the aryl moieties of said aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl, and aryl-(C1-C6)alkyloxyare independently selected from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moieties of said heteroaryl-(C1-C6)alkyl and heteroaryl-(C1-C6)alkyloxy are independently selected from wherein the aryl moiety is selected from phenyl and naphthyl, heteroaryl selected from pyridyl, furyl, tetrahydrofuryl, thienyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl and benzothiazolyl, and wherein said aryl and heteroaryl and the aryl and heteroaryl moieties of said heteroaryl-(C1-C6)alkyl, aryl-(C1-C6)alkyl, (C1-C6)alkoxycarbonylaryl,aryl-(C1-C6)alkyloxyandheteroaryl-(C1-C6)alkyloxymayoptionally be substituted with one or more substituents independently selected from chloro, bromo, (C1-C6)alkyl, (C1-C6)alkoxy, -S-(C1-C6)alkyl, -SO-(C1-C6)alkyl, -SO2-(C1-C6)alkyl, hydroxy-(C1-C6)aIkyl and trifluoromethyl.
PCT/US1993/006446 1992-09-28 1993-07-12 Substituted pyrimidines for control of diabetic complications WO1994007867A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU46697/93A AU683620B2 (en) 1992-09-28 1993-07-12 Substituted pyrimidines for control of diabetic complications
US08/406,947 US5728704A (en) 1992-09-28 1993-07-12 Substituted pyridmidines for control of diabetic complications
CA002145640A CA2145640C (en) 1992-09-28 1993-07-12 Substituted pyrimidines for control of diabetic complications
EP93917043A EP0662962A1 (en) 1992-09-28 1993-07-12 Substituted pyrimidines for control of diabetic complications
KR1019950701168A KR950703539A (en) 1992-09-28 1993-07-12 SUBSTITUTED PYRIMIDINES FOR CONTROL OR DIABETIC COMPLICATIONS
NO951155A NO306598B1 (en) 1992-09-28 1995-03-27 Substituted pyrimidines to combat diabetic complications
US08/980,559 US5866578A (en) 1992-09-28 1997-12-01 Substituted pyrimidines for control of diabetic complications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95222292A 1992-09-28 1992-09-28
US07/952,222 1992-09-28

Publications (1)

Publication Number Publication Date
WO1994007867A1 true WO1994007867A1 (en) 1994-04-14

Family

ID=25492671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/006446 WO1994007867A1 (en) 1992-09-28 1993-07-12 Substituted pyrimidines for control of diabetic complications

Country Status (15)

Country Link
US (2) US5728704A (en)
EP (1) EP0662962A1 (en)
JP (1) JP2789134B2 (en)
KR (1) KR950703539A (en)
AU (1) AU683620B2 (en)
CA (1) CA2145640C (en)
FI (1) FI934224A (en)
HU (1) HU220669B1 (en)
IL (1) IL107085A (en)
MY (1) MY115288A (en)
NO (1) NO306598B1 (en)
NZ (1) NZ254550A (en)
TW (1) TW284759B (en)
WO (1) WO1994007867A1 (en)
ZA (1) ZA937142B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0640599A1 (en) * 1993-08-26 1995-03-01 Ono Pharmaceutical Co., Ltd. 4-Aminopyrimidine derivatives
EP0791355A1 (en) 1996-02-29 1997-08-27 Pfizer Inc. Method of reducing tissue damage associated with ischemia
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1998039343A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
US5880130A (en) * 1993-12-09 1999-03-09 Zeneca Limited 4,6-dianilino-pyrimidine derivatives, their preparation and their use as tyrosine kinase inhibitors
WO2000014095A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
WO2000059510A1 (en) * 1999-04-01 2000-10-12 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
US6156755A (en) * 1997-03-13 2000-12-05 Aventis Pharma Deutschland Gmbh Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures
WO2002038551A1 (en) * 2000-11-10 2002-05-16 F. Hoffman-La Roche Ag Pyrimidine derivatives and their use as neuropeptide y receptor ligands
AU2003242500C1 (en) * 1998-09-09 2003-09-25 Metabasis Therapeutics, Inc. Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
EP1402895A1 (en) * 1997-03-07 2004-03-31 Metabasis Therapeutics, Inc. Benzimidazole inhibitors of fructose 1,6-biphosphatase
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
WO2005110413A2 (en) 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
US7229993B2 (en) 2002-03-13 2007-06-12 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
CN100349904C (en) * 1998-09-09 2007-11-21 症变治疗公司 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US7893063B2 (en) 2004-07-09 2011-02-22 Astrazeneca Ab 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2789134B2 (en) * 1992-09-28 1998-08-20 ファイザー・インク． Substituted pyrimidines control diabetic complications
HUP0000838A3 (en) * 1997-04-15 2001-04-28 Csir Extract containing steroid-glucosid, process for its isolation and synthesis, pharmaceutical composition containing it having appetite suppressant activity
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
DE60009777T2 (en) * 1999-04-01 2004-08-19 Pfizer Products Inc., Groton Association for treatment and prevention of diabetes
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
CN1740182A (en) * 1999-12-22 2006-03-01 症变治疗公司 Novel bisamidate phosphonate prodrugs
AU2001245532B2 (en) * 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
WO2002043762A2 (en) * 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
MXPA03004871A (en) * 2000-11-30 2003-08-19 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
US7081470B2 (en) * 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
EP1247809A3 (en) * 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
AU2002341257A1 (en) * 2001-10-15 2003-04-28 Pfizer Products Inc. Three dimensional crystal structure of human sorbitol dehydrogenase and uses thereof
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
BR0306988A (en) * 2002-01-18 2004-11-23 Pharmacia Corp Pyridazinones substituted as p38 inhibitors
AU2003249369A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040082627A1 (en) * 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050261292A1 (en) * 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EP1778250A2 (en) * 2004-08-18 2007-05-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
EP1805142A4 (en) * 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc Novel pyridine compounds, process for their preparation and compositions containing them
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
AU2005316739A1 (en) * 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007083182A2 (en) * 2006-01-19 2007-07-26 Orchid Research Laboratories Limited Novel heterocycles
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
US8158667B2 (en) * 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
ES2371393T3 (en) 2007-03-12 2011-12-30 Zadec Aps ROOIBOS ANTIDIABETIC EXTRACT.
DK2142529T3 (en) 2007-04-27 2014-02-10 Purdue Pharma Lp TRPV1 ANTAGONISTS AND APPLICATIONS THEREOF
JP5704924B2 (en) 2008-02-01 2015-04-22 オーキッド リサーチ ラボラトリーズ リミティド New heterocyclic compounds
JP2013528172A (en) 2010-05-21 2013-07-08 ファイザー・インク 2-Phenylbenzoylamide
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2012120414A2 (en) 2011-03-04 2012-09-13 Pfizer Inc. Edn3-like peptides and uses thereof
EP2723732B1 (en) 2011-06-22 2017-01-18 Purdue Pharma LP Trpv1 antagonists including dihydroxy substituent and uses thereof
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
ES2836500T3 (en) * 2016-06-21 2021-06-25 Univ Columbia Aldose reductase inhibitors and methods of using them
US11590131B2 (en) 2017-07-28 2023-02-28 Applied Therapeutics, Inc. Compositions and methods for treating galactosemia
CN108101883B (en) * 2018-01-31 2018-11-13 佳木斯大学附属第一医院 It is a kind of to be used to prevent drug of diabetic retinopathy and preparation method thereof
MX2021008533A (en) 2019-01-18 2021-08-19 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1063014A (en) * 1950-06-14 1954-04-29 Wellcome Found Pyrimidine derivatives and their preparation
GB959699A (en) * 1961-06-09 1964-06-03 May & Baker Ltd New pyrimidine derivatives
EP0055693A1 (en) * 1980-12-23 1982-07-07 Ciba-Geigy Ag Use of phenyl pyrimidines as protecting agents for culture plants against phytotoxic damage caused by herbicides
EP0384370A1 (en) * 1989-02-22 1990-08-29 Hoechst Aktiengesellschaft Substituted pyrimidine derivatives, process for their preparation, and their use as tool
EP0470616A2 (en) * 1990-08-10 1992-02-12 Hoechst Aktiengesellschaft Substituted pyrimidin derivatives, process for their preparation and their use as reagent
WO1992004333A1 (en) * 1990-08-31 1992-03-19 Nippon Shinyaku Co., Ltd. Pyrimidine derivative and medicine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
FR2489141A1 (en) * 1980-09-03 1982-03-05 Sevifra SURGICAL APPARATUS FOR PRECISE CUTTING OF THE CORNEA
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US5066659A (en) * 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
US5102908A (en) * 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0637473B2 (en) * 1985-10-11 1994-05-18 三共株式会社 Lactam compound
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4835410A (en) * 1988-02-26 1989-05-30 Black & Decker Inc. Dual-mode corded/cordless system for power-operated devices
GB8810203D0 (en) * 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
GB8902405D0 (en) * 1989-02-03 1989-03-22 Ici Plc Heterocyclic compounds
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US5039672A (en) * 1990-04-05 1991-08-13 Pfizer Inc. Heterocyclic compounds as aldose reductase inhibitors
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
GB9016984D0 (en) * 1990-08-02 1990-09-19 Ici Plc Aniline derivatives
JP2789134B2 (en) * 1992-09-28 1998-08-20 ファイザー・インク． Substituted pyrimidines control diabetic complications

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1063014A (en) * 1950-06-14 1954-04-29 Wellcome Found Pyrimidine derivatives and their preparation
GB959699A (en) * 1961-06-09 1964-06-03 May & Baker Ltd New pyrimidine derivatives
EP0055693A1 (en) * 1980-12-23 1982-07-07 Ciba-Geigy Ag Use of phenyl pyrimidines as protecting agents for culture plants against phytotoxic damage caused by herbicides
EP0384370A1 (en) * 1989-02-22 1990-08-29 Hoechst Aktiengesellschaft Substituted pyrimidine derivatives, process for their preparation, and their use as tool
EP0470616A2 (en) * 1990-08-10 1992-02-12 Hoechst Aktiengesellschaft Substituted pyrimidin derivatives, process for their preparation and their use as reagent
WO1992004333A1 (en) * 1990-08-31 1992-03-19 Nippon Shinyaku Co., Ltd. Pyrimidine derivative and medicine

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525604A (en) * 1993-08-26 1996-06-11 Ono Pharmaceutical Co., Ltd. 4-aminopyrimidine derivatives
EP0640599A1 (en) * 1993-08-26 1995-03-01 Ono Pharmaceutical Co., Ltd. 4-Aminopyrimidine derivatives
US5880130A (en) * 1993-12-09 1999-03-09 Zeneca Limited 4,6-dianilino-pyrimidine derivatives, their preparation and their use as tyrosine kinase inhibitors
MY118982A (en) * 1996-02-29 2005-02-28 Pfizer Method of reducing tissue damage associated with ischemia
US5932581A (en) * 1996-02-29 1999-08-03 Pfizer Inc. Method of reducing tissue damage associated with ischemia
EP0791355A1 (en) 1996-02-29 1997-08-27 Pfizer Inc. Method of reducing tissue damage associated with ischemia
AU714038B2 (en) * 1996-02-29 1999-12-16 Pfizer Inc. Method of reducing tissue damage associated with ischemia
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
EP1402895A1 (en) * 1997-03-07 2004-03-31 Metabasis Therapeutics, Inc. Benzimidazole inhibitors of fructose 1,6-biphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6110903A (en) * 1997-03-07 2000-08-29 Sankyo Company Ltd. Benzimidazole inhibitors of fructose 1,6-bisphosphatase
WO1998039343A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6294672B1 (en) 1997-03-07 2001-09-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of Fructose-1,6-biphosphatase
US7285543B2 (en) 1997-03-07 2007-10-23 Metabasis Therapeutics, Inc. Purine inhibitors of fructose-1,6-bisphosphatase
US6399782B1 (en) 1997-03-07 2002-06-04 Metabasis Therapeutics, Inc. Benzimidazole inhibitors of fructose 1,6-bisphosphatase
US6967193B1 (en) 1997-03-07 2005-11-22 Metabasis Therapeutics, Inc. Purine inhibitors of fructose-1,6-bisphosphatase
US6156755A (en) * 1997-03-13 2000-12-05 Aventis Pharma Deutschland Gmbh Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures
CZ297264B6 (en) * 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
US7312219B2 (en) 1998-09-09 2007-12-25 Metabasis Therapeutics, Inc. Heteroaromatic inhibitors of fructose 1,6-bisphosphatase
AU2003242500C1 (en) * 1998-09-09 2003-09-25 Metabasis Therapeutics, Inc. Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
US6489476B1 (en) 1998-09-09 2002-12-03 Metabasis Therapeutics, Inc. Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase
CN100349904C (en) * 1998-09-09 2007-11-21 症变治疗公司 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
AU2003242500B2 (en) * 1998-09-09 2006-11-02 Metabasis Therapeutics, Inc. Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
WO2000014095A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
KR100818845B1 (en) * 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. Novel Heteroaromatic Inhibitors of Fructose 1,6-Bisphosphatase
AU768720B2 (en) * 1999-04-01 2004-01-08 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
US6869943B2 (en) 1999-04-01 2005-03-22 Pfizer Inc Sorbitol dehydrogenase inhibitors
US6936600B2 (en) 1999-04-01 2005-08-30 Pfizer Inc Sorbitol dehrydrogenase inhibitors
US6660740B1 (en) 1999-04-01 2003-12-09 Pfizer Inc Sorbitol dehydrogenase inhibitors
US6602875B2 (en) * 1999-04-01 2003-08-05 Pfizer Inc Sorbitol dehydrogenase inhibitors
US6414149B1 (en) 1999-04-01 2002-07-02 Pfizer Inc. Sorbitol dehydrogenase inhibitors
WO2000059510A1 (en) * 1999-04-01 2000-10-12 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6657060B2 (en) 2000-11-10 2003-12-02 Hoffman-La Roche Inc. Pyrimidine derivatives
WO2002038551A1 (en) * 2000-11-10 2002-05-16 F. Hoffman-La Roche Ag Pyrimidine derivatives and their use as neuropeptide y receptor ligands
US6995159B2 (en) 2001-06-21 2006-02-07 Pfizer Inc. 5-HT receptor ligands and uses thereof
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US7229993B2 (en) 2002-03-13 2007-06-12 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
WO2005110413A3 (en) * 2004-05-19 2006-07-13 Solvay Pharm Gmbh Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
WO2005110413A2 (en) 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
AU2005244450B2 (en) * 2004-05-19 2010-08-19 Solvay Pharmaceuticals Gmbh Medicaments containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
US7893063B2 (en) 2004-07-09 2011-02-22 Astrazeneca Ab 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer

Also Published As

Publication number Publication date
AU4669793A (en) 1994-04-26
ZA937142B (en) 1995-03-23
CA2145640A1 (en) 1994-04-14
US5728704A (en) 1998-03-17
IL107085A0 (en) 1993-12-28
FI934224A0 (en) 1993-09-27
FI934224A (en) 1994-03-29
TW284759B (en) 1996-09-01
EP0662962A1 (en) 1995-07-19
HU9302734D0 (en) 1993-12-28
JP2789134B2 (en) 1998-08-20
IL107085A (en) 2001-01-11
KR950703539A (en) 1995-09-20
NO306598B1 (en) 1999-11-29
JPH07507072A (en) 1995-08-03
HUT65531A (en) 1994-06-28
NO951155D0 (en) 1995-03-27
NO951155L (en) 1995-05-26
AU683620B2 (en) 1997-11-20
CA2145640C (en) 2001-01-30
HU220669B1 (en) 2002-04-29
NZ254550A (en) 1997-08-22
MY115288A (en) 2003-05-31
US5866578A (en) 1999-02-02

Similar Documents

Publication Publication Date Title
CA2145640C (en) Substituted pyrimidines for control of diabetic complications
EP1041068B1 (en) Compounds for treating and preventing diabetic complications
US5594015A (en) Thiazolidine derivatives for the treatment of psoriasis
CA2198564C (en) Method of reducing tissue damage associated with non-cardiac ischemia
EP1047675A1 (en) Chemokine receptor antagonists and methods of use therefor
US6110951A (en) Thiazolidine derivatives for the treatment of hypertension
HU199839B (en) Process for producing new 1',2'-dihydro-spiro square brackets open imidazolidine-4,4'(3'h)-quinoline square brackets closed derivatives and pharmaceutical compositions comprising same as active ingredient
IE801212L (en) Spiro-hydantoin derivatives
US5066659A (en) Spiro-heteroazalones for treatment of diabetic complications
US4604406A (en) N-[6-methoxy-5-(perfluoroalkyl)-1-naphtholyl]-N-methylglycines and their thionaphthoyl analogs
US20030040531A1 (en) Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist
PL147400B1 (en) Method of obtaining novel derivatives of spiro imidazolidine
JP2002326987A (en) New triazine compound useful as sorbitol dehydrogenase inhibitor
EP0028485B1 (en) Spiro-imidazolones for alleviating diabetes-associated conditions, processes for preparing them, and pharmaceutical compositions containing them
EP0469837B1 (en) Use of a compound in the manufactur of a medicament for lowering of blood uric acid levels
PL143070B1 (en) Method of obtaining novel hidantoine derivatives
DuPriest et al. Spiro [fluoreneisothiazolidin] one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors
KR860001870B1 (en) Process for preparing imidazolidinedione derivatives
AU2959999A (en) Preventives/remedies for urinary disorder
MXPA00003243A (en) Compounds for treating and preventing diabetic complications
JPH08239366A (en) New parabanic acid derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR NO NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 254550

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1993917043

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08406947

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2145640

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1993917043

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1993917043

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993917043

Country of ref document: EP